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ABSTRACT
The effects of creatine supplementation on endurance 
and metabolism during high intensity intermittent exercise 
were examined using 18 males and females (age 19-26). The 
subjects were randomly divided into 2 groups (creatine and 
placebo) and the testing proceeded in two phases. During 
phase 1 both groups received a placebo. During phase 2 the 
placebo group again received a placebo, while the creatine 
group received creatine (3.75g - 5 times daily for 5 days). 
Testing consisted of high intensity intermittent cycling 
protocols on a stationary cycle ergometer. Both groups 
performed all test bouts (in random order) in phase 1 and 
again in phase 2. Testing consisted of: Continuous (Bout A) - 
Continuous pedaling at 150% V 02 peak until exhaustion.
30/60 (Bout B) - 30 seconds of pedaling at 150% V 02 peak 
followed by 60 seconds rest, repeated until exhaustion. 20/40 
(Bout C) - 20 seconds pedaling at 150% V 02 peak followed by 
40 seconds rest, repeated until exhaustion. 10/20 (Bout D) - 
10 seconds pedaling at 150% V 02 peak followed by 20 
seconds rest, repeated until exhaustion. The placebo group 
showed no significant change in time to exhaustion from
phase 1 to phase 2 for any of the bouts tested. The creatine 
group, however, showed a significant increase in time to 
exhaustion on all bouts. Bout D was impacted significantly 
more than the other bouts with a more than twofold increase 
in time to exhaustion, (note that bout D was truncated before 
subjects reached exhaustion because even at twice the 
performance time of phase 1 subjects reported feeling very 
little fatigue and the ability to continue indefinitely). Oxygen 
consumption did not change from phase 1 to phase 2 for the 
placebo group, while the creatine group showed a significantly 
lower rate of oxygen consumption on bouts D and C. Blood 
lactic acid values were also lower on bouts C and D for the 
creatine group only. Therefore creatine supplementation 
significantly impacted performance of high intensity 
interm ittent exercise.
CHAPTER 1 ■ INTRODUCTION
Short duration (5-20 second) maximal intensity 
exercise relies mainly on the phosphagen system to meet 
energy demands and anaerobic glycolysis to replenish 
adenosine triphosphate (ATP) and phosphocreatine (PCr) 
stores. This type of high intensity exercise can be maintained 
for only brief periods unless it is performed in intermittent 
fashion. Astrand et al. (1960) showed that when a subject 
exercised at a very high intensity (412 watts), exercise could 
be maintained for only 3 minutes. If the subject then 
exercised at the same intensity for 1 minute and then rested 
for 1 minute, exercise could be maintained for 24 minutes 
before the subject became completely exhausted. However, 
since rest periods were included, the total work done per unit 
of time was reduced. Astrand et al. (1960) found that if both 
the total work done in 30 minutes and the work to rest ratio 
is held constant (1:2) that the most important factor in 
determining the onset of fatigue is the length of the exercise 
period. It was found that blood lactate levels increased with 
work to rest ratios of 60:120 seconds and 30:60 seconds, but 
not a ratio of 10:20 seconds. Therefore, high intensity exercise 
of a 10 second duration could yield the same amount of work
in 30 minutes as the longer exercise periods with no blood 
lactate accumulation and no feeling of fatigue. Astrand et al. 
(1960) suggested that during the shorter work periods ATP 
demand was met by oxidative metabolism utilizing myoglobin 
oxygen stores, since lactate levels did not increase. Later 
research (Saltin et al. 1976 and Essen 1978) showed that 
during intense exercise lasting 5 to 20 seconds that ATP and 
PCr levels were decreased. These ATP and PCr stores were 
replenished during rest periods. More recent work by 
Gaitanos et al. (1993) suggests that work bouts of only 6 
seconds can proceed with a significant contribution from 
anaerobic glycolysis. It was demonstrated that 6 second 
maximal cycle sprints resulted in increased lactate levels 
indicating a significant contribution from anaerobic glycolysis. 
This is possibly because the ATP and PCr stores were depleted 
more rapidly at this higher intensity level. These results 
suggest that intermittent exercise with brief work periods 
(10s) may rely mainly on the phosphagen system to meet 
energy demands with anaerobic glycolysis contributing 
significantly only during longer work periods (>30s) or during 
shorter work periods if the intensity is high.
It has also been shown by Gaitanos et al. (1993) that 
during the final bout (bout 10) of 6 second maximal cycle 
sprints that the contribution of glycolysis to ATP resynthesis 
was decreased and that the contribution from PCr to ATP 
production was increased from 49.6% (bout 1) to 80% (bout 
10). Also, Bogdanis et al. (1993) found that the recovery of 
power output during 30 second cycle ergometer sprints is 
correlated with muscle PCr levels and not lactate levels.
These findings suggest that PCr plays a dominant role in the 
maintenance and recovery of power during high intensity 
interm ittent exercise.
PCr levels can be increased in skeletal muscle through 
oral creatine supplementation. Harris et al. (1992) found that 
supplementation with 5g of creatine monohydrate four to six 
times a day for a total of 20-30g for two or more days 
resulted in a significant increase in total creatine content of 
the quadriceps femoris muscle. Creatine uptake during the 
first two days accounted for 32% of the administered dose 
with 20% to 40% of the sequestered creatine present as PCr. 
Total creatine content in skeletal muscle was increased by up 
to 50%. Further work by Greenhaff et al. (1993) showed that
oral creatine supplementation accelerated PCr resynthesis 
following intense isometric contractions.
Creatine supplementation has been shown to enhance 
performance during high intensity exercise. Balsom et al. 
(1993) found a smaller decline in work output during high 
intensity intermittent cycling following creatine 
supplementation. There was also a decrease in lactate and 
hypoxanthine accumulation. In addition, Greenhaff et al. 
(1993) showed that plasma ammonia accumulation was lower 
during and after exercise during the final 10 contractions of 
five bouts of 30 maximum voluntary isokinetic contractions. 
These decreases in plasma ammonia and hypoxanthine 
accumulation (indicating a reduced adenine nucleotide 
degradation) indicate an increased reliance on creatine 
phosphate rather than the myokinase reaction to remove 
ADP. The increased PCr levels in skeletal muscle following 
creatine supplementation may have enhanced performance of
intense exercise by increasing the rate of ATP resynthesis 
during exercise (Greenhaff et al„ 1993A) and the rate of PCr 
resynthesis during recovery from intense exercise (Greenhaff 
et al. 1993B).
1.1 - Project Rationale
In normal daily activities muscular work is seldom 
performed for an extended period of time and so steady state 
is seldom achieved. Most muscular work involves short bursts 
of activity followed by periods of rest (intermittent exercise). 
Also many popular sports involve short bursts of activity 
followed by a rest period or a period of reduced activity 
(football, basketball, baseball, tennis) and so performance in 
these sports may be related to the ability to maintain high 
performance levels in intermittent exercise rather than 
maximum aerobic power or endurance. Since many of these 
activities involve extended performance of intermittent 
exercise, any treatment that could prolong the onset of fatigue 
during these activities would be of considerable benefit. 
Although creatine has led to a greater amount of total work 
during repeated Wingate tests (Earnest et al., 1993) and a 
smaller decline in work output during high intensity cycling 
(Balsom et al., 1993) it has not yet been demonstrated that 
creatine supplementation can prolong the performance of high 
intensity intermittent exercise.
1.2 - Hypothesis
1. Creatine supplementation will increase total work output 
during all of the exercise bouts.
2. Plasma lactic acid accumulation will be lower during 
exercise following creatine supplementation versus placebo.
3. Exercise will proceed with a lower rate of oxygen 
consumption during the creatine supplementation period.
4. Response to creatine supplementation will be inversely 
related to fitness level and body weight.
5. The 10/20 bout will be impacted by creatine 
supplementation to a greater extent than the other bouts.
6. Urinary creatinine will be significantly increased by 
creatine supplementation.
1.3 - Objectives
1. Determine if creatine supplementation increases total work 
output during high intensity intermittent exercise by 
examining time to exhaustion during several intermittent 
exercise bouts on creatine versus placebo.
2. Determine if creatine supplementation leads to a lower 
accumulation of lactic acid during high intensity intermittent 
exercise.
4. Determine if oxygen consumption during intermittent 
exercise is affected by creatine supplementation.
5. Determine which bout (continuous, 10/20, 20/40,30/60) 
benefits the most from creatine supplementation.
6. Determine if body weight or fitness level is related to 
magnitude of response to creatine supplementation.
7. Determine if urinary creatinine concentration is increased 
following creatine supplementation.
CHAPTER 2 - LITERATURE REVIEW
2.1 - Intermittent exercise
Intermittent exercise can be defined as exercise 
consisting of repeated bouts of work interspersed with 
recovery periods. Intermittent exercise has an advantage over 
continuous exercise in that it can be maintained for a longer 
period of time before fatigue ensues. Astrand (1970) showed 
that a subject whose V 02max was 4.6 liters.min'1 could 
exercise at 350 watts for 8 minutes. If the same subject 
exercised at 350 watts in an intermittent fashion, 3 minutes of 
exercise alternated with 3 minute rest periods, the subject 
could continue exercise for one hour. However, since rest 
periods were included there was less work done per unit of 
time than continuous exercise at the same intensity. In a 
second series of experiments Astrand (1970) exercised the 
same subject (same subject used in the previous study) at 412 
watts for 30 minutes in several bouts; continuous, 60 sec. 
work /120 sec. rest, 30 sec. work / 60 sec. rest, 10 sec. work / 
20 sec. rest. By holding the work to rest ratio constant (1/2) 
the same amount of work would be done per unit of time 
during all of the bouts. This allowed Astrand to investigate the 
effect of adjusting the length of the work period, while
9maintaining the same work rate, on the performance of 
intermittent exercise. Even though the same amount of work 
was produced in 30 minutes (247 KJ) in all of the 
intermittent bouts there was no feeling of fatigue and lactate 
levels did not exceed 2 mM during the intermittent bout with 
the shortest work period (10/20), while during the 60/120 
bout lactate levels rose to 15.7 mM and the subject could 
continue for only 24 minutes. Intermediate results were 
found with the 30/60 intermittent bout. Thus the critical 
factor in determining the onset of fatigue was the length of 
the work bout. Astrand et al. (1970) suggested that during the 
10/20 intermittent bout that ATP demand was met by 
oxidative metabolism of myoglobin oxygen stores which were 
replaced during the rest periods. In the longer bouts 
myoglobin oxygen stores were not adequate to supply all of 
the needed ATP and so anaerobic glycolysis was initiated to 
generate the necessary ATP. There was a greater reliance on 
anaerobic glycolysis to replenish ATP supplies as the length of 
the bout increased and this lead to a greater production and 
accumulation of lactate and a more rapid onset of fatigue.
Essen (1978) has shown that the overall metabolic 
response to intermittent exercise (in terms of substrate
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utilization and lactate accumulation) is more similar to that of 
continuous exercise at about half of the load. There are 
several reasons for this finding. The most obvious is that 
metabolic demand is greatly reduced during the rest periods. 
Also, myoglobin oxygen stores are reloaded allowing for a 
greater contribution of oxidative metabolism (Astrand et al. 
1960). Essen (1978) has shown that glycogen depletion 
patterns are similar for intermittent or continuous exercise of 
the same intensity, ruling out differences in fiber recruitment 
as the factor controlling the divergent metabolic response. 
Essen (1978) also mentions that the increase in the key 
metabolic regulators, ATP, CP and citrate during the rest 
periods act to synergistically affect metabolism, retarding 
glycolysis and allowing for a greater utilization of lipids and a 
lower utilization of carbohydrates.
During muscular contraction there is a considerable 
utilization of ATP by the myosin ATPases. However, ATP 
concentration is not decreased until PCr levels are depleted 
significantly. PCr donates a high energy phosphate to ADP to 
reform ATP via the reaction catalyzed by creatine 
phosphokinase (CPK). Bessman and Geiger (1981) have 
presented evidence that PCr is locally concentrated near the
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MM-isozyme of creatine phosphokinase (CPK) where it would 
be positioned optimally for the replenishment of ATP during 
muscle contraction. The skeletal muscle PCr stores provide 
enough energy for about 10 seconds of maximal intensity 
exercise (Miller, 1992).
In addition to the CPK reaction, the myokinase reaction 
can buffer the increase in ADP by the following reaction: ADP 
+ ADP —myokinase--> ATP + AMP. However, during low 
intensity exercise the high affinity cytosolic CPK competes 
better than myokinase for the available ADP and thus AMP 
levels are not significantly increased. During high intensity 
exercise, however, ADP levels rise significantly, providing 
ample substrate for myokinase (Hochachka and Somero,
1984). The AMP formed is converted to IMP and NH4 via the 
AMP deaminase reaction. This process is further enhanced by 
a low pH (the pH optima for AMP deaminase is 6.1- 
6.5)(Dobson et al., 1987). Therefore during high intensity 
exercise IMP serves as an adenine nucleotide sink with the 
net effect being a reduction in the total adenine nucleotide 
pool. It has been shown that during high intensity 
intermittent exercise ATP concentration decreases at the 
beginning of each successive bout and that the drop in ATP is
stoichiometrically matched with the rise in IMP (Dobson et al., 
1987). A reduction in ATP concentration has been linked to 
fatigue during high intensity exercise (Nagesser et al., 1992). 
Also increased IMP concentration has been correlated with a 
reduction in force production (Nagesser et al., 1992 and 
Westra et al. 1986). Berden et al. (1986) have shown that 
there is a binding site for IMP on the actin-myosin complex 
and have suggested that IMP might have a direct influence on 
the contractile apparatus. Therefore, during high intensity 
intermittent exercise the decrease in ATP on successive bouts 
and the concomitant increase in IMP may contribute to the 
fatigue response.
The magnitude of high energy phosphate store (ATP and 
PCr) restoration during recovery periods has also been linked 
to performance during intermittent exercise. It was shown 
that the recovery of PCr correlated with the recovery of 
power output (r=.76, p<0.05) during repeated bouts of 30 
second cycle ergometer sprints with 90 second recovery 
periods (Bogdanis et al. , 1993).
During high intensity exercise it is the depletion of ATP 
and the consequent accumulation of ADP and AMP that begins 
to activate glycolysis by stimulating phosphofructokinase
(PFK) (Passonneau and Lowry, 1962). Also, glycogenolysis is 
activated almost immediately due to the calcium calmodulin 
stimulation of phosphorylase b (Miller, 1992). Although 
anaerobic glycolysis can contribute significantly to ATP 
production, the maximum rate of ATP production is at best 
about half that of the phosphagen system. It has been 
estimated by McGilvery (1975) that the maximum power 
output for skeletal muscle utilizing ATP, ADP and PCr 
(phosphagen system only) is 96-360 pmoles ATP gm wet 
weight ’’ min For muscle using glycogen fermentation or 
glycogen oxidation the values are 60.0 and 30.0 p moles ATP 
gm wet weight '* min 1 respectively. Therefore if exercise 
intensity is maximal, ATP utilization exceeds demand 
resulting in a decrease in performance.
During very high intensity intermittent exercise, as 
previously mentioned, the length of the work bout becomes a 
primary factor in determining the onset of fatigue (Astrand, 
1960). As the length of the work bout is increased the 
contribution of glycolysis to ATP production increases. 
Gaitanos et al. (1993) have shown that maximal intensity 
intermittent exercise leads to a reduction in the ATP 
production rate of glycolysis on each subsequent bout. This
led to a lower ATP production rate overall (from 14.9 mM/Kg 
dry wt. To 5.3 mM/Kg dry wt per minute) and thus a drop in 
performance. Also, glycogen degradation was decreased by 10 
fold. It was proposed that the large increase in lactate and the 
concomitant decrease in muscle pH was responsible for the 
reduction in glycolytic and glycogenolytic rates. Consequently, 
as the length of the work bout is increased, there is an 
increasing reliance on glycolysis to maintain ATP levels. 
However, the capacity of glycolysis to generate ATP may be 
reduced during each subsequent bout due to the reduction in 
muscle pH. Golnick et al. (1974), have shown that if exercise 
intensity exceeds maximal aerobic power there is an 
increasing reliance on fast twitch, glycolytic fibers and a 
concomitant increase in muscle lactate concentration. During 
high intensity exercise (above V 02 max.) this would inevitably 
lead to fatigue because of the inability to maintain ATP levels 
due to an ever decreasing rate of ATP production.
It can be concluded then that there are at least 4 
important metabolic considerations that affect the 
performance of high intensity intermittent exercise:
1. The maintenance of high energy phosphates during the 
exercise bout (or according to Atkinson, the maintenance of
the adenylate energy charge): This is accomplished by first
utilizing the stored phosphagens. Then as the phosphagens 
become significantly depleted anaerobic glycolysis is activated 
to resynthesize the store of high energy phosphates. (Recall 
that the maximum rate of ATP production by anaerobic 
glycolysis is 60 pmoles ATP gm wet weight ' '  min 1 . If the 
rate of ATP utilization exceeds this rate then the ability to 
maintain performance would be determined entirely by the 
quantity of stored phosphagens.)
2. Adequate recovery of high energy phosphates during the 
rest periods: (As previously mentioned the recovery of power 
output during cycle ergometer sprints was correlated with the 
recovery of PCr stores. )
3. The restoration of the ability to generate ATP during the 
exercise bouts: Recall that Gaitanos et al. (1993) found that 
repeated bouts led to a fall in the rate of ATP production 
overall (14.9 mM/Kg dry wt. To 5.3 mM/Kg dry wt) and thus 
a drop in performance. PCr recovery was not a limiting factor 
(since the rate of ATP production from PCr was not reduced). 
This would suggest that the recovery of glycolysis (the ability 
to generate ATP at the desired rate) between bouts would also 
be an important consideration (provided that the exercise
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bout is of sufficient intensity or duration to require a 
significant contribution from glycolysis.)
4. The management of adenine nucleotides: Recall that ATP 
concentrations are decreased at the beginning of each bout 
during intermittent exercise and the decrease in the 
concentration of ATP is stoichiometrically matched with the 
rise in IMP (Dobson et al., 1987).
2.2 _r_.Creatine and Control of the Creatine Pool
Creatine exists in skeletal muscle in a concentration of 
approximately 125 mmol/kg dry weight and is present in 
phosphorylated and free forms (Greenhaff, 1994). The two 
forms of creatine are in a reversible equilibrium.
Approximately 60% of the muscle creatine in skeletal muscle 
at rest is in the form of creatine phosphate (Greenhaff, 1994). 
Creatine phosphate (PCr) is the primary high energy 
phosphate store in vertebrate skeletal muscle. PCr has a AG of 
-10.3 kcal/mole allowing it to donate a high energy phosphate 
to ADP for ATP resynthesis in the following reaction catalyzed
by creatine phosphokinase: PCr + ADP <-----> ATP + Creatine.
PCr levels are highest in fast twitch skeletal muscle with 
typical values approaching 30 pmoles/gm wet weight.
Bessman and Geiger (1981) have presented evidence that PCr
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is locally concentrated near the MM-isozyme of creatine 
phosphokinase (CPK) where it would be positioned optimally 
for the replenishment of ATP during muscle contraction.
Skeletal muscle contains 95% of the body’s 
approximately 120g of creatine (Greenhaff, 1994). The control 
of this creatine pool is achieved primarily by the regulation of 
the synthesis of creatine by the transamidinase enzyme. 
Although skeletal muscle contains the primary creatine pool, 
creatine is not synthesized in skeletal muscle. Exogenous 
synthesis of creatine occurs in the kidney, liver and pancreas. 
Creatine synthesis is controlled by negative feedback 
inhibition of the transamidinase enzyme by creatine (Walker, 
1973). Since the location of the bulk of the creatine pool 
(skeletal muscle) and the sites of synthesis of creatine (liver, 
kidney and pancreas) are physically separated, the control of 
creatine synthesis must be regulated in part by the small 
amount of circulating creatine. Additionally, it has been shown 
by Crim et al. (1976) that feeding of the creatine precursors 
glycine and arginine stimulated creatine synthesis in excess of 
the amount required to maintain steady state. It was 
proposed that (a) substrate limitation was controlling creatine 
synthesis or (b) transamidinase enzyme inhibition by creatine
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was reversed by the precursors or (c) synthesis of the 
transamidinase enzyme was increased by precursor feeding or 
(d) that insulin concentrations were elevated in the plasma 
due to precursor feeding (insulin has been shown to enhance 
creatine uptake into skeletal muscle by Koszalka et al. 1972).
Since creatine is not synthesized in skeletal muscle and 
does not readily cross the cell membrane there must be a 
second level of control of the size of the creatine pool in 
skeletal muscle, the transport of creatine into skeletal muscle. 
The Na+ dependent creatine transporter in skeletal muscle has 
been identified and its cDNA has recently been cloned and 
sequenced (Guimbal and Kilimann, 1993). The transporter 
specifically interacts with the amidine group of creatine (Fitch 
et al., 1968). Fitch and Shields (1966) have shown that 
creatine uptake in rat skeletal muscle is an energy requiring 
saturable process that is capable of replacing about 4% of the 
total skeletal muscle creatine each day. It has been shown by 
Loike et al. (1988) that creatine transport is down regulated 
in the presence of extracellular creatine concentrations of 45 
pM. It was also shown that there was a downregulation of 
creatine transporters by extracellular creatine.
Although creatine can be synthesized de novo from the 
precursors glycine and alanine, the skeletal muscle creatine 
pool has been shown to respond to creatine supplementation. 
In a recent study Harris et al. (1992) have shown that 
supplementation with 5g of creatine monohydrate four to six 
times a day for 2 or more days resulted in a significant 
increase in the total creatine content of the quadriceps 
femoris muscle in man. The increase in the total creatine pool 
was in excess of 20% with 20% or more of the increase being 
present as creatine phosphate. Uptake was greatest during the 
first two days of supplementation accounting for 32% of the 
administered dose. It was also shown that exercise 
apparently increased the uptake of creatine. Creatine uptake 
was greater in subjects with low initial levels of creatine.
2.3 - Creatine Supplementation Studies
Since Harris et al. (1992) demonstrated that skeletal 
muscle creatine can be increased by creatine supplementation, 
several studies have demonstrated the beneficial effects of 
creatine supplementation. Using a high intensity intermittent 
cycling protocol (880 watts) Balsom et al. (1993) showed that 
oral creatine supplementation (5 6-g doses daily for 6 days) 
led to a smaller decline in work output from baseline than a
placebo group. The creatine group also showed a decrease in 
lactate accumulation (from 7.0 to S.l mmol I'1) and a lower 
oxygen consumption (2.84 to 2.78 1 min*1). Plasma 
hypoxanthine accumulation was also lowered (21 to 16.7 pm ol
l '1) indicating a reduced adenine nucleotide degradation. The 
increased availability of PCr may have led to a preferential 
use of creatine phosphokinase to rephosphorylate ADP to ATP 
(ADP + PCr —creatine phosphokinase—> ATP + Cr) rather than 
myokinase (ADP + ADP —myokinase—>ATP + AMP) with a 
reduced production of NH4 and IMP (AMP —AMP deaminase— 
> NH4 + IMP). These findings have been supported by 
Greenhaff et al. (1993) who showed that during bouts of 
maximal isokinetic contractions that there was a lower 
accumulation of ammonia following creatine supplementation. 
In the same study it was shown that during the final 10 
contractions of each bout that torque was better preserved on 
creatine vs. controls. Since it had been proposed that creatine 
may be enhancing performance by increasing the rate of high 
energy phosphate resynthesis during recovery (Balsom et al.
1993) this was investigated by Greenhaff et al. (1994). Muscle 
biopsy samples were taken during recovery from intense
electrically evoked isometric contractions. Creatine increased 
muscular creatine levels by 15-32% and substantially 
increased PCr resynthesis during recovery (6%). It has also 
been shown that creatine supplementation can lead to a 
decrease in ATP degradation during exercise (Greenhaff et al.
1994). Cr supplementation had no effect on ATP degradation 
during the first bout (30 second bouts of maximal isokinetic 
contractions) but reduced ATP loss by 50% compared to pre 
creatine values during the second bout even though more 
work was done.
Creatine supplementation has not always been shown to 
enhance performance, however. Cooke et al. (1995) showed 
that during high-intensity short-duration cycle sprints 
creatine supplementation (the same supplementation regime 
shown by Harris et al. 1992 to increase muscle creatine levels) 
did not lead to enhanced performance. However this study 
used 15 second maximal sprints (as opposed to the 6 second 
sprints used by Balsom et al., 1993). In maximal sprints of 
this duration the large contribution of glycolysis may 
overshadow any improvements in the phosphagen system due 
to creatine supplementation. Recall that Gaitanos et al. (1993) 
have shown that during 6 second maximal bouts that there is
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a significant contribution of glycolysis. This would be expected 
to increase as the duration of the bout is increased. Also, 
Balsom et al. (1993) have shown that creatine 
supplementation does not enhance endurance exercise. There 
was no improvement in run times during a treadmill run to
exhaustion at supramaximal intensities (>V 02 max.) and
creatine supplementation actually led to an increase in run 
times for a 6 km terrain run. It was proposed that this 
increase in run times might be attributed to a 2.3 kg weight
gain for the creatine group.
Therefore creatine supplementation appears to enhance 
exercise performance during very brief (<10 seconds) high 
intensity exercise that stresses primarily the phosphagen 
system. Creatine can also lead to a lower lactate accumulation 
(because energy provision during the exercise bout can be 
met by a larger contribution of the phosphagen system with 
decreased reliance on glycolysis) and a lower accumulation of 
N H 4 and hypoxanthine (due to a decreased reliance on 
myokinase to replenish ATP and thus less substrate available 
to AMP deaminase).
Although it seems likely that the increases in 
performance due to creatine supplementation are due to an
increase in total creatine and phosphocreatine pools, other 
possibilities have not been investigated. However, since 
creatine clearance is a non saturable process and occurs very 
rapidly (the half life of circulating creatine may be less than 
two hours) (Crim et al. 1976), it is probable that during the 
aforementioned performance studies that circulating creatine 
levels would have been reduced to baseline levels during the 
testing periods. Therefore the observed increases in 
performance would have been due to some residual effect of 
creatine supplementation. The most likely residual effect 
would be an increase in skeletal muscle creatine and 
phosphocreatine concentrations.
CHAPTER 3 - MATERIALS AND METHODS
3.1 - Basic Design
Eighteen subjects were divided into two groups, a 
placebo-control and an experimental. The experimental group 
was given a placebo before and during the first phase of 
testing and was given creatine supplementation before and 
during the second phase of testing. The control group received 
a placebo before and during the first and second phases of 
testing. Both groups underwent identical testing protocols. The 
testing then proceeded in two phases (see figure 3.1) as 
follows:
Phase l(p lacebo)
Day 1 - Begin placebo administration
- V 02 peak test 
Day 5 - Exercise bout at 150% V 02 peak*
Day 7 - Exercise bout at 150% V 02 peak*
Day 9 - Exercise bout at 150% V 02 peak*
Day 11 - Exercise bout at 150% V 02 peak*
- end placebo supplementation regimen 
Phase 2 (creatine-placebo)
Day 20 - begin creatine or placebo supplementation regimen
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Day 25 - (two weeks following last test)
-(after 5 days on creatine supplement or placebo)
- Exercise bout at 150% V 02 peak*
Day 27 - Exercise bout at 150% V 02 peak*
Day 29 - Exercise bout at 150% V 02 peak*
Day 31 - Exercise bout at 150% V 02 peak*
- end supplementation regimen 
*Exercise bouts consisted of four different protocols. One bout 
was performed per testing session and the bouts were 
assigned in random order during each phase. The bouts 
consisted of:
Bout A-Continuous
Bout B-30 seconds work;60 seconds rest
Bout C-20 seconds work:40 seconds rest
Bout D-10 seconds work:20 seconds rest.
Also, finger prick blood draws and V 02 measurements were
taken during each test. Details on blood draws and analysis 
and V 02 measures will be given in a later section.
3.2 - Subjects
Subjects were apparently healthy (apparently healthy = 
satisfactory answers on PARQ - see appendix B) male and 
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Figure 3.1. S tudy F low chart
Both groups consisted of 5 males and 4 females (see table 3.1. 
for subject characteristics). The Subjects gave written consent 
to act as a subject in a research experiment and the 
experiment proceeded following the approval of the LSU 
Institutional Review Board.
Table 3.1. S ub jec t C h a ra c te ris tic s
GROUP Creatine Group Placebo Group
V02 PEAK 227 Watts 214.3 Watts
V02 PEAK 41.76 ml/kgxmin-1 40.51 ml/kgxmin-1
GENDER 5 male 4 female 5 male 4 female
AGE 23.4 23.3 24.4 23.8
WEIGHT 205.4 lbs 119.5 lbs 206.2 lbs 128.3 lbs
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3.3 - Supplementation
Creatine supplementation consisted of 3.75g creatine 
monohydrate 5 times daily (5 tablets 5 times daily for a total 
of 18.75 g/day) for 5 days followed by 2.25g creatine once 
daily (3 tablets once daily) for 6 days. Creatine 
supplementation was given to the creatine group only, before 
phase 2 testing only. Placebo supplementation consisted of 
l.Og of placebo (calcium) 5 times daily (5 tablets 5 times 
daily) for 5 days followed by .6g placebo once daily (3 tablets 
once daily) for 6 days. The placebo was indistinguishable in 
appearance from the creatine supplement. Placebo regimen 
administration began 5 days prior to phase 1 (both groups) 
and phase 2 testing (placebo group) and ended following the 
last testing session during each phase.
3.4 - V 07 peak
Subjects were instructed to refrain from intense 
physical exercise the day before testing and fasted for at least 
4 hours prior to the test session (Note - V 02 peak measures 
were used to standardize the proceeding intermittent work 
bouts and have no other experimental significance). The seat 
height was adjusted to subject satisfaction and recorded to 
standardize its position for each test. Subjects first engaged in
a standardized warm up procedure consisting of 5 minutes of 
pedaling at a low tension level. Subjects began the test by 
pedaling at 100 rpm against no load for 1 minute. The load 
was then be increased by 50 watts each minute until the 
subject was no longer able to maintain the required pedaling 
rate of 100 rpm. The work rate associated with the last 
completed stage (last 1 minute stage) was considered the V 02 
peak. Expired respiratory data (V 02 and VC02) was collected 
continuously using the Quinton Q-Plex I.
3.5 - Standardized Exercise Bouts
Bout A - Subjects repeated the standardized warm up 
procedure administered before the V 02 peak test. Subjects 
then pedaled at 100 rpm at 150% of their V 02 peak work rate
until exhaustion (the subject could no longer maintain the
required pedaling rate). Bout B - Subjects repeated the 
standardized warm up procedure. Subjects then began 
intermittent exercise consisting of repeated 100 rpm cycling 
bouts at 150% V 02 peak for 30 seconds followed by 60 
seconds rest. Bout C - Standardized warm up followed by 100
rpm cycling (150% V 02 peak) for 20 seconds followed by 40
seconds rest. Bout D - 100 rpm (150% V 02 peak) cycling for 10 
seconds followed by 20 seconds rest. All intermittent bouts
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were repeated until exhaustion (the subject could no longer 
maintain the required pedaling rate).
3.6 - Blood draws and analysis
One hundred microliters of blood was collected in 
heparinized microcapillary tubes by the finger prick method. 
New lancelets were used for each prick and aseptic conditions 
were maintained throughout. Plasma samples were taken on 
the following schedule:
Continuous bout - Before exercise, immediately after exercise, 
and 3 minutes post exercise.
10/20 intermittent bout - Immediately prior to exercise, 
immediately after the fourth 10 second pedaling period (2 
minutes), immediately after the eighth 10 second pedaling 
period(4 minutes) and immediately post exercise.
20/40 intermittent bout - Immediately prior to exercise, after 
the second 20 second pedaling period (2 minutes), after the 
fourth 20 second pedaling period (4 minutes) and 
immediately post exercise.
30/60 intermittent bout - Immediately prior to exercise, 
immediately after the first 30 second pedaling period (30 
seconds), immediately after the second 30 second pedaling 
period (2 minutes) and immediately post exercise.
Blood samples were placed in an ice water bath and 
were centrifuged immediately following the test and stored at 
-70° C for further analysis. Blood lactate concentration was 
determined using the Analox GM7 micro-stat analyzer (Analox 
Instruments Ltd. , 8 Godkhawk Industrial Estate, Brackenbury 
Road, Hammersmith, London W6 OBQ, England). The micro- 
stat analyzer functions by measuring the oxygen change when 
oxyreductase enzymes react with their substrates under 
controlled semi-anaerobic conditions. For lactate analysis the 
reaction proceeds as follows:
L-lactate + 0 2 — Lactate oxyreductase—> pyruvate +H20 2 
Lactate measures were performed in duplicates and were 
repeated if measures differed by 0.3 mmol/1.
3.7 - Oxveen Consumption
Expired respiratory data (V 02 and VC02) was collected 
continuously using the Quinton Q-Plex I during all exercise 
tests.
3.8 - Urinary Creatinine
Urine samples were collected from both groups during 
phase 2. The first sample was collected before the phase 2 
supplementation period begins. Samples two and three were 
collected on day 2 and 3 of supplementation respectively.
3 1
Urinary creatinine was determined by the use of Sigma kit 
#555-A .
3.9 - Statistical Analysis
Time to exhaustion for each group was analyzed using 
ANOVA with repeated measures (1 within=phase, 1 
between=time). Post-ANOVA analysis involved, where 
appropriate, the use of Tukey’s range test. The 
experimentwise error rate was set at p<=0.05 and was 
maintained throughout all post-ANOVA tests. Each bout was 
analyzed independently for each group for differences in 
lactate and respiratory data at specific time intervals using 
ANOVA with repeated measures (1 within=phase, 1 
between=time). Differences due to the supplementation 
regime were determined by comparing Phase 1 (with all time 
periods pooled) with phase 2 (with all time periods pooled). 
Differences within groups in urinary creatinine concentration 
were determined by using ANOVA with repeated measures. 
Post ANOVA analysis involved the use of Tukey’s range test. 
The relationship of fitness level and body weight with 
increases in total work output was examined utilizing multiple 
linear regression.
CHAPTER 4 - RESULTS
4.1 Time to Exhaustion
Creatine supplementation had a significant impact on 
time to exhaustion (and thus total work output). The creatine 
supplementation group showed a greater than 100% increase 
in time to exhaustion on bout D, phase 2 (p<0.01) (see fig.4.1), 
while the placebo group showed no significant change (see fig.
4.2). Bout D was impacted significantly more than the other 
bouts with a greater than twofold increase in time to 
exhaustion. Note that for all subjects on creatine, phase 2 bout 
D was truncated at twice the performance time of phase 1. At 
this time point all subjects on creatine reported feeling very 
little fatigue and the ability to continue indefinitely. The bout 
was truncated due to factors related to subject compliance and 
because a twofold increase in time to exhaustion was 
sufficient to show a significant impact of creatine 
supplementation. Bout C was also significantly impacted by 
creatine supplementation with a 61.9% increase in time to 
exhaustion (PcO.Ol), while the placebo group showed no 
significant change from phase 1 to phase 2 (see fig.4.1 and
4.2). The creatine group showed a 61.0% increase in time to 
exhaustion (p<0.01) on bout B, Phase 2, while the placebo
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group, again, showed no significant change. Finally, bout A 
was also significantly impacted by creatine supplementation 
(p<0.01) with a 23.5% increase in time to exhaustion, while 
again, there was no significant change for the placebo group 
(see fig.4.1 and 4.2). The gain in time to exhaustion was 
significantly different for each bout (P<0.05) with the 
magnitude of the increase being greater as the length of the 
work period becomes shorter (ie. D>C>B>A).
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Figure 4.1. Time to Exhaustion - Phase x Bout, 
C rea tine  G roup. (Data are presented as means + 
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Figure 4.2. Time to Exhaustion - Phase x Bout, 
P lacebo G roup. (Data are presented as means + 
standard deviations)
4,2 Oxygen Consumption
Oxygen consumption increased with time, as expected 
for all exercise bouts. The creatine supplementation group, 
however, showed a significantly lower oxygen consumption 
rate (p<0.01) during bouts D (fig. 4.3) and C (fig. 4.5) for 
phase 2. The placebo group showed no significant change in 
oxygen consumption rate during these bouts (fig. 4.4 and 4.6). 
Both groups showed a significantly lower rate of oxygen 
consumption (p<0.01) during bout B, phase 2 (tig. 4.7 and 
4.8). For bout A neither group showed a significantly lower 
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Figure 4.5. V 02 For Phase 1 and 2, Bout C, 
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Figure 4.7. V 02 For Phase 1 and 2, Bout B, 



















































Figure 4.10. V02 For Phase 1 and 2, Bout A,
Placebo Group
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4.3 Plasma Lactic Acid
Plasm a lactic acid concentration increased with 
exercise a s  expected. Lactate concentration was significantly 
lower (P<0.01) for the creatine group on bout D, phase 2 (fig. 
4.11) while the placebo group showed no significant change 
from phase 1 to 2 (fig. 4.12). Bout C also showed a  significant 
decrease (p<0.01) from phase 1 to phase 2 for the creatine 
group only (fig. 4.13), while the placebo group showed no 
significant change (fig. 4.14). Also for bout B there was a 
significant decrease in lactate concentration from phase 1 to 
phase 2 (p<0.01) for the creatine group (fig. 4.15), while the 
placebo group showed no change (fig.4.16). There was no 
change by either group for bout A from phase 1 to 2 (fig. 
4.17and 4.18).
4.4 Urinary Creatinine
Urinary creatinine concentration w as significantly 
(p<0.01) elevated on day 2 and 3 of supplementation for the 
creatine group (see fig. 4.19), while the placebo 
supplementation group showed no change (see fig. 4.20). This 
increased creatinine excretion suggests that subjects 
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Figure 4.15. Lactate For P hase  1 and 2, Bout B, 
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Figure 4 .17 . Lactate For Phase 1 and 2, Bout A, 
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Figure 4.19. Urinary C reatin ine For C reatine And 
Placebo G roups (Data are presented as means + 
standard deviations. ‘Significantly different from p r e ­
supplementation values, p<0.01)
4.5 Regression of Body Weight and Fitness on Improvement in 
Total Work Output
Neither body weight (r=0.074) nor fitness level 
(maximum VOz during the VOz peak test)(r—0.038) or the 
combination (r=0.076) were a good predictor of the magnitude 
of improvement in total work output due to creatine 
supplementation on bouts C, B and A (note that bout D was not 
included because this bout was truncated a t twice the 
performance time of phase 1.
CHAPTER 5 - DISCUSSION
Creatine supplementation (5g of creatine monohydrate 
four to six times a day for 2 or more days) has been shown to 
significantly increase the total creatine content of the 
quadriceps femoris muscle in man (Harris et al. 1992). The 
increase in the total creatine pool was in excess of 20%, with 
20% or more of the increase being present as creatine 
phosphate. Greenhaff et al. (1994) have also found a 25% 
increase in total creatine content of the vastus lateralis after 
creatine supplementation. Although skeletal muscle contains 
95% of the body’s creatine pool (Greenhaff, 1994), creatine is 
not synthesized in muscle. Therefore the size of the creatine 
pool in skeletal muscle is regulated in part by blood creatine 
concentrations (Crim et al., 1976). In the present study, all 
subjects on creatine showed a significantly elevated urinary 
creatinine concentration on day 2 and 3 of the 
supplementation period. Subjects in the placebo group showed 
no significant change. Assuming a daily urine output of .6 to 
2.5 liters/day, creatine turnover averaged 1.2 - 5.0 
grams/day for the placebo group, which agrees with Fitch and 
Shield’s (1966) estimate of 2.0 grams/day under normal 
conditions. Creatine turnover for the creatine group on
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supplementation day 2 and 3, based on these estimates, would 
be 6 to 10 times this value. This increase in urinary creatinine 
indicates that creatine entered the bloodstream in significant 
quantities and was subsequently eliminated by excretion in 
the urine. It is therefore likely that the supplementation 
regime used in the present study provided an increased 
availability of circulating creatine and thus successfully 
elevated skeletal muscle creatine content.
An increase in total creatine content and the 
concomitant increase in PCr due to creatine supplementation 
has been shown to:
1. Reduce the decrease in ATP concentration following high 
intensity exercise (Greenhaff, 1994).
2. Increase the rate of PCr recovery following high intensity 
exercise (Greenhaff, 1994B).
3. Reduce the decline in power output following repeated 
bouts of maximal isokinetic cycling (Birch et al., 1994) .
4. Lower plasma lactic acid and hypoxanthine accumulation 
during high intensity intermittent exercise (Balsom et al., 
1993).
As such, creatine supplementation may be able to blunt the 
metabolic consequences of high intensity exercise and
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therefore be of ergogenic benefit. Surprisingly, it has not yet 
been demonstrated whether creatine supplementation can 
enhance total work output during high intensity intermittent 
exercise. Therefore the present study was undertaken to 
investigate the effects of creatine supplementation on the 
performance of 4 different high intensity intermittent work 
bouts.
The most significant finding of the present study is that 
creatine supplementation increased total work output (as 
measured by time to exhaustion) during all exercise bouts (A, 
6 , C, and D), with the greatest response occurring during bout
D. As previously mentioned, bout D was truncated at twice the 
performance time of phase 1. The decision to truncate the 
bout was based on the request by several subjects to 
terminate the bout prior to exhaustion as they felt as though 
they could continue indefinitely. For example, subject #7 (the 
first subject on creatine to perform phase 2, bout D) 
continued for 10 minutes to exhaustion on phase 1. On phase 
2, at 29 minutes (nearly a threefold increase) the subject 
reported feeling very little fatigue and felt capable of 
continuing indefinitely. At the request of the subject the bout 
was terminated. Based on this experience and due to the
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request by several subjects to truncate the bout prior to 
exhaustion, all of the subsequent phase 2, bout D tests for the 
creatine group were truncated at twice the performance time 
of phase 1. Supporting this decision was the fact that at this 
time point all subjects experienced little fatigue and felt 
capable of continuing indefinitely.
It is generally accepted that the energy requirements 
(ATP) of brief (<20 seconds), high intensity exercise are met 
by the available phosphagen stores (ATP, PCr), the resynthesis 
of these phosphagens and the anaerobic degradation of 
glucose. A reduction in performance occurs in this type of 
physical activity when ATP and PCr stores become depleted 
and lactate, the end product of anaerobic glycolysis, begins to 
accumulate. It could be anticipated that any mechanism which 
delays the occurrence of either of these events should extend 
the time an individual can work at this intensity level i.e. be 
of ergogenic benefit. Data from the current study 
demonstrates that creatine supplementation substantially 
delays the onset of fatigue. This ergogenic benefit may have 
been achieved by better meeting the energy needs of the 
exercising muscles through one or more of the following 
mechanisms:
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1. Increasing the concentration of stored phosphagens.
2. Increasing the rate of PCr resynthesis during the recovery 
periods.
3. Decreasing the reliance on myokinase to buffer the drop in 
ATP levels, thus lowering the production of IMP and the 
concomitant loss in adenine nucleotides.
4. Decreasing the reliance on glycolysis to provide ATP during 
the work bouts, hence reducing lactate accumulation and its 
ergolytic effect of reduced pH.
Employing a dose similar to the present study (20g/day 
versus 18.75g/day in the present study), Harris et al. (1992) 
and Greenhaff et al. (1994) demonstrated a significant 
increase in muscle creatine concentration (20% and 25% 
respectively) due to supplementation. Therefore, it is most 
probable that the supplementation regime used in the present 
study resulted in an increase in muscle creatine and PCr 
concentrations. An increased concentration of stored 
phosphagens would have allowed more work to be done 
before high energy phosphates were depleted significantly, or 
a reduced depletion of high energy phosphates for same 
amount of work. A reduced depletion of high energy 
phosphates during the work periods would result in a reduced
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activation of ATP generating metabolic pathways. Note that 
this is supported by the fact that both aerobic (reduced V 02) 
and anaerobic (reduced lactate) metabolism during the 
exercise bouts were reduced following creatine 
supplementation. Therefore the increased quantity of stored 
phosphagens due to creatine supplementation may have 
reduced the metabolic consequences of high intensity exercise 
(reduced ATP and PCr concentrations and increased lactate) 
and consequently delayed the onset of fatigue.
In addition, creatine supplementation may have 
extended time to exhaustion by increasing the rate of PCr 
resynthesis during the recovery periods of the intermittent 
bouts. Greenhaff et al. (1993) have shown that creatine 
supplementation accelerates the rate of phosphocreatine 
resynthesis following intense muscle contractions. This 
increase in PCr resynthesis resulted in a greater concentration 
of PCr at the beginning of each subsequent exercise period 
during intermittent exercise. Furthermore, the recovery of PCr 
following exercise is highly correlated with the recovery of 
power output during repeated cycle sprints (Bogdanis et al., 
1993). It was found that a higher concentration of PCr prior 
to each subsequent work bout led to a greater power output
and thus more work done during the bouts. Therefore, in the 
present study, creatine may have impacted performance by 
accelerating the rate of PCr resynthesis during recovery, thus 
increasing the concentration of PCr at the beginning of each 
subsequent exercise period. With regards to increasing the 
rate of PCr resynthesis, Greenhaff et al. (1993) suggested that 
creatine feeding may have accelerated the rate of PCr 
resynthesis from mitochondrial ATP. It is argued that the 
increase in muscle creatine due to supplementation may have 
increased the rate of flux through the CPK reaction at the 
mitochondrial membrane. The availability of creatine may 
possibly be a limiting factor in PCr resynthesis following 
intense exercise because:
A) The Km of CPK for creatine (19mmol/l) is very close to the 
concentration of creatine in skeletal muscle at rest and after 
maximal exercise (Bergmeyer, 1965).
B) The affinity of CPK for creatine is much lower than for ATP. 
As a result, even after high intensity exercise when creatine 
levels are highest, CPK would not be operating near Vmax 
because of a limiting supply of creatine (creatine 
concentration at this time would still not be significantly 
higher than the Km of CPK for creatine). Therefore the
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sequestering of creatine by CPK might be rate limiting. 
Greenhaff et al. (1993) argue that after supplementation 
muscle Cr. levels may have reached 44 mmol/1, significantly 
higher than the km for creatine (19 mmol/1). It is proposed 
that this near saturation of CPK is the mechanism whereby 
creatine supplementation accelerates the rate of PCr recovery 
following high intensity exercise. This increased rate of PCr 
resynthesis could have enhanced performance during the 
present study by providing a greater high energy phosphate 
pool for each succeeding work bout. Again, this increase in the 
high energy phosphate pool would reduce the metabolic 
impact of the exercise bouts.
Increased PCr levels caused by creatine 
supplementation might also affect the management of adenine 
nucleotide concentrations via the myokinase reaction. As 
exercise is initiated ATP is degraded rapidly. PCr buffers this 
drop in ATP concentration via the reaction catalyzed by CPK 
(ADP + PCr—CPK-->ATP + Cr.). Therefore ATP concentration is 
not significantly reduced until PCr levels are depleted. A 
second reaction, catalyzed by myokinase (ADP + ADP— 
myokinase-> ATP + AMP), competes with CPK for the 
available ADP. During low intensity exercise the higher
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affinity CPK competes more successfully than myokinase for 
the available ADP. During high intensity exercise, however, 
ADP levels rise significantly, providing ample substrate for 
myokinase which converts two molecules of ADP to ATP and 
AMP (Hochachka and Somero, 1984). The AMP formed is in 
turn converted to IMP and NH4 via the AMP deaminase 
reaction. Therefore, during high intensity exercise there is a 
shunting of adenine nucleotides from ATP to IMP with the 
result being a net loss of adenine nucleotides from the muscle 
cell. This reaction shunts adenine nucleotides away from the 
resynthesis of ATP.
Evidence is available which demonstrates that during 
high intensity intermittent exercise, ATP concentration 
continues to decrease with each successive exercise period 
and that the drop in ATP levels is stoichiometrically matched 
with a rise in IMP (Dobson et al., 1987). Some of the adenine 
nucleotides lost in the production of IMP are restored during 
the recovery periods via the purine nucleotide cycle. However, 
there is likely to be a progressive loss of adenine nucleotides 
during each successive bout of high intensity exercise.
Therefore there would be a shunting of adenine nucleotides 
away from the pools available for ATP synthesis, leading to a
reduction in ATP levels during each subsequent exercise 
period. A reduction in ATP concentration during exercise has 
been linked to a decrease in force production (Nagesser et al., 
1992). In addition to this metabolically driven decrease in 
force production (due to a decreased ATP concentration) an 
increased IMP concentration may physically interfere with 
force production of the actin-myosin complex (Nagesser et al., 
1992 and Westra et al. 1986). Berden et al. (1986) have 
shown that there is a binding site for IMP on the actin-myosin 
complex and have suggested that IMP might have a direct 
influence on the contractile apparatus due to an, as yet 
undetermined mechanism. Therefore, during high intensity 
intermittent exercise there is a progressive decrease in ATP 
levels on successive bouts due to the loss of adenine 
nucleotides to the production of IMP. This decrease in ATP 
levels at the beginning of each successive exercise period may 
contribute to the fatigue response. Also, the increased IMP 
concentration may physically interfere with force production 
of the actin-myosin complex by an unknown mechanism. Due 
to the high intensity nature of the exercise bouts, this cause of 
fatigue is likely to have occurred during the placebo 
supplementation regimen.
The aforementioned cause of fatigue (decrease in ATP 
and an increase in IMP) might have been attenuated by 
creatine supplementation due to a decreased reliance on 
myokinase to buffer the rise in ADP (by providing more PCr 
substrate for the competing CPK reaction). This would result in 
a lower production of IMP and a lower total adenine 
nucleotide loss. This reduced adenine nucleotide loss would 
have resulted in better maintenance of ATP levels during 
intermittent exercise by providing more adenine nucleotides 
for ATP resynthesis rather than shunting the adenine 
nucleotides to the synthesis of IMP. In support of this it has 
been shown that creatine supplementation can reduce 
hypoxanthine (Balsom et al., 1993) and ammonia (Greenhaff 
et al., 1993) accumulation during high intensity intermittent 
exercise. Plasma ammonia and hypoxanthine are established 
markers of adenine nucleotide loss during high intensity 
exercise (Harris et al., 1991). This reduced adenine nucleotide 
loss due to creatine supplementation is associated with a 
reduction in the decrease in ATP concentration following high 
intensity exercise (Greenhaff, 1994). This also would result in 
better maintenance of the high energy phosphate pool and
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thus greater phosphagen stores preceeding each successive 
bout of exercise.
Finally, creatine supplementation may have reduced the 
reliance on glycolysis to replace ATP during the bouts. During 
high intensity intermittent exercise the ability to generate 
ATP rapidly via glycolysis may limit performance. As high 
intensity exercise is initiated there is a rapid degradation of 
high energy phosphates. Glycolysis is then engaged to buffer 
the drop in ATP. It has been shown by Gaitanos et al. (1993) 
that after a 6 second cycle sprint PCr levels were decreased 
by 57%. Bogdanis et al. (1993) have found that after a 30 
second cycle sprint both PCr and ATP contents were reduced 
to 17.6 and 71% of their initial values respectively. This 
decrease in PCr and ATP increases flux through glycolysis 
almost immediately by the removal of the inhibitory effect of 
these metabolites on PFK and phosphorylase (Morgan and 
Parmeggiani, 1964, Mansour, 1963). Gaitanos et al. (1993) 
have found that glycolysis can provide up to 50% of the ATP 
required during maximal work bouts as short as 6 seconds. As 
the length of the work period is increased the contribution 
from glycolysis would be expected to increase as well. This 
reliance on glycolysis to maintain ATP levels may be a
primary factor in determining the onset of fatigue (Astrand, 
1960). Although glycolysis is required to replace the rapidly 
diminishing ATP stores, maximal intensity intermittent 
exercise leads to a reduction in the ATP production rate of 
glycolysis for each subsequent bout. In a study by Gaitanos et 
al. (1993) this reduction in the ability of glycolysis to generate 
ATP during intermittent exercise led to a lower ATP 
production rate overall (from 14.9 mM/Kg dry wt. to 5.3 
mM/Kg dry wt per minute) after 10 six second sprints and 
thus a drop in performance. Also, glycogen degradation was 
decreased by 10 fold. It was proposed that the large increase 
in lactate and the concomitant decrease in muscle pH was 
responsible for the reduction in glycolytic and glycogenolytic 
rates. Danforth (1965) has shown that a lowering of pH slows 
glycolysis by inhibiting PFK and phosphorylase. Consequently, 
as the volume of work is increased, there is an increasing 
reliance on glycolysis to maintain ATP levels. However, the 
capacity of glycolysis to generate ATP may be reduced during 
each subsequent bout due to the reduction in pH. This would 
inevitably lead to a reduction in performance because of an 
inability to maintain the necessary ATP production rate.
In the present study plasma lactate accumulation was 
reduced following creatine supplementation. Assuming that 
lactate efflux and clearance were similar, this would suggest a 
reduced reliance on anaerobic glycolysis due to creatine 
supplementation. As previously mentioned creatine 
supplementation has been shown to:
A) Reduce the decline in ATP concentration following high 
intensity exercise (Greenhaff, 1994).
B) Increase the rate of PCr recovery following high intensity 
exercise (Greenhaff, 1994B)
C) Lower plasma lactic acid and hypoxanthine accumulation 
(indicating a reduction in adenine nucleotide loss) during high 
intensity intermittent exercise (Balsom et al., 1993).
All of these factors would result in greater high energy 
phosphate stores at the beginning of each subsequent exercise 
bout. This might allow more work to be done prior to ATP 
levels being decreased significantly. This would result in a 
delay in the accumulation of the PFK stimulators ADP and 
AMP. Also creatine supplementation has been shown to 
reduce ammonia production, another stimulator of PFK. Thus, 
the overall effect is the reduced stimulation of anaerobic 
glycolysis following creatine supplementation. In the present
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study this could have resulted in a lower reliance on 
glycolysis during each exercise bout (This is supported by the 
observed reduction in plasma lactate concentrations.)- A 
decreasing reliance on glycolysis would result in a lower 
production of lactate and thus a smaller reduction in pH. A 
reduction in pH has been linked to a reduced ability of 
glycolysis to generate ATP (Gaitanos et al., 1993). Therefore a 
reduced decline in pH might extend time to exhaustion by 
maintaining the ATP production rate of glycolysis.
A reduced reliance on glycolysis might also explain the 
greater impact of creatine supplementation on bout D. Due to 
the relatively short work periods during bout D (10 seconds), 
it is likely that glycolysis contributed less to ATP production 
during this bout than during bouts C, B, and A (note that 
lactate accumulation was lower during bout D than during the 
other bouts). Therefore even a small reduction in the 
stimulation of glycolysis would represent a relatively large 
reduction in the contribution of glycolysis during bout D. 
Consequently, during longer work bouts, a similarly small 
reduction in the already large contribution from glycolysis 
would be expected to have less effect. This is best exemplified 
by comparing bout D to Bout A. Note that lactate accumulation
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was significantly lower during bout D following creatine 
supplementation. Conversely, bout A showed no significant 
change.
In summary, creatine supplementation may have 
increased PCr levels resulting in an increased phosphagen 
concentration, a more rapid resynthesis of PCr during the 
recovery periods and a reduced adenine nucleotide loss. A 
reduced adenine nucleotide loss would provide more adenine 
nucleotides for the resynthesis of ATP rather than the 
production of IMP. All of these factors would result in a 
better maintenance of high energy phosphate concentrations 
during high intensity intermittent exercise. Also, because of 
the high intensity nature of the work bouts, anaerobic 
glycolysis was engaged to buffer the depletion of ATP.
However, the ability to generate ATP via glycolysis is reduced 
following repeated bouts of exercise due to a reduction in 
muscle pH. Creatine supplementation reduced lactate 
accumulation (indicating a reduced reliance on glycolysis to 
produce ATP) and thus may have better preserved the ability 
of glycolysis to generate ATP. The reduction in lactate 
accumulation was greatest during bout D. This may explain 
the relatively large impact of creatine supplementation on
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bout D. Therefore because of a higher concentration of stored 
phosphagens prior to each subsequent exercise period during 
the bouts, the metabolic impact (decreased ATP and PCr 
concentrations and increased lactate) of the exercise bouts 
was reduced, thus delaying the onset of fatigue.
In addition to reducing lactate accumulation and 
increasing total work output, oxygen consumption was also 
impacted by creatine supplementation. The rate of oxygen 
consumption was decreased during bout D and C following 
creatine supplementation while the placebo group showed no 
change during these bouts. Since oxygen consumption was 
measured at the same time points on creatine versus placebo, 
the same amount of work was done at a lower net oxygen 
cost. This suggests that exercise efficiency (cost/work) was 
affected by creatine supplementation.
Creatine may have delayed the increase in oxygen 
consumption upon the initiation of exercise. A decrease in ATP 
and an increase in ADP upon the initiation of exercise serves 
as a stimulator of mitochondrial respiration (Scott, 1995). An 
increase in PCr levels due to creatine supplementation might 
have delayed the decrease in the ATP/ADP ratio that is 
responsible for stimulating mitochondrial respiration. In
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support of this argument it has been found that competition 
between aerobic and anaerobic systems for ADP can inhibit 
mitochondrial respiration (Gatt, S., and Racker, E., 1959). CPK 
would be poised to have such an influence on mitochondrial 
respiration. An increase in PCr might allow for a more rapid 
rephosphorylation of ADP by CPK and thus reduce the ADP 
concentration that might stimulate respiration.
Alternatively, a reduction in fatigue due to creatine 
supplementation may have delayed changes in neuromuscular 
coordination that may have occurred due to fatigue. It was 
noted (although not actually measured) that subjects showed 
an increased body movement as they approached exhaustion 
(i:e. swaying side to side and leaning forward). This may have 
represented a shift in muscle recruitment (due to fatigue) 
from the primary muscles used during cycling to secondary 
muscles that are in a less favorable position to produce force 
(i.e. gluteus maximus, hamstrings). Utilizing these secondary 
muscles would result in a need to generate greater force to 
produce the same amount of external work, since these 
muscles are in a less favorable position to produce force. As a 
result oxygen consumption would be increased. If creatine 
supplementation delayed the fatigue of the primary muscles
involved in cycling there would be a delay in this shift in 
whole muscle recruitment patterns and thus a lower rate of 
oxygen consumption. Note that although muscle recruitment 
patterns were not measured, changes in recruitment patterns 
cannot be ruled out as a plausible explanation for the decrease 
in oxygen consumption and may present a plausible 
explanation since both aerobic (decreased V 02) and anaerobic 
(decreased lactate) metabolism were reduced following 
supplem entation.
It was proposed that fitness levels might affect response 
to creatine supplementation since Harris et al. (1992) have 
shown that creatine uptake due to creatine feeding was 
greatest in subjects that had a lower initial level of creatine. 
Because exercise training has been shown to increase PCr 
stores (Macdougall et al., 1977) the relationship between 
fitness level (highest V 02 during V 02 peak test) and 
magnitude of response to creatine supplementation was 
investigated. No significant relationship between these two 
variables was found. Perhaps the index of fitness chosen has 
little relationship to muscle creatine levels. Alternatively, 
creatine may have impacted performance regardless of initial 
creatine levels. Also, the relationship of body weight to
magnitude of response to creatine supplementation was 
investigated. The subjects encompassed a broad range in body 
weights from 115 to 290 pounds. Therefore the lightest 
subject in the study would have received nearly three times 
the relative dose (dose/body wt.) of the heaviest subject. 
However, no relationship between body weight and response 
to creatine supplementation was observed. This might suggest 
that the dose administered to the lighter subjects might have 
been in excess of what was necessary to produce a response 
since nearly 1/3 of that relative dose led to a similar response 
in the largest subject.
CHAPTER 6 - SUMMARY AND CONCLUSIONS
The purpose of the present study was to determine if 
creatine supplementation could increase total work output 
during high intensity continuous and intermittent exercise. 
The results indicate that creatine does enhance the 
performance of high intensity intermittent exercise with a 
lower accumulation of lactate and a lower rate of oxygen 
consumption. Creatine supplementation may have enhanced 
performance by affecting the management of adenine 
nucleotides and high energy phosphates during the bouts. The 
effects of creatine supplementation on intermittent exercise 
are greatest when the length of the work bout is short. This 
may be due to a greater relative reduction in the contribution 
from glycolysis during the shorter work periods.
Although the ergogenic benefit of creatine 
supplementation is likely to result from the impact on cellular 
metabolism of an increase in creatine and PCr stores, other 
possibilities may exist. In addition to metabolic perturbations, 
other nonmetabolic mechanisms of fatigue have been 
proposed. For example Bigland-Ritchie et al. (1979) have 
proposed that fatigue could result from an impairment of the 
central nervous system resulting in a less than optimal
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frequency of motor nerve firing. Also, with fatigue a 10 to 20 
mV reduction in membrane polarization has been observed 
and this decreased membrane polarization has been 
associated with a reduced Ca++ transient amplitude (Hanson 
and Peterson, 1971). Both the reduced frequency of motor 
nerve firing and a reduced Ca++ transient amplitude would 
result in reduced force production. It is not known if creatine 
supplementation can affect these fatigue mechanisms as well. 
Also, alterations in blood flow and cardiac output would be 
expected to affect the performance of intermittent exercise. 
These cardiovascular parameters were not investigated in the 
present study. In conclusion, though an increase in creatine 
and PCr stores seems to be the most likely explanation of the 
observed ergogenic effect, these alternative explanations 
remain to be investigated.
Due to the observed ergogenic impact, creatine 
supplementation might be recommended for athletes 
participating in sports involving repeated, short bursts of 
activity followed by rest or periods of reduced activity (i.e. 
football, soccer, tennis, hockey etc...) Creatine supplementation 
has been associated with no known side effects as creatine is 
rapidly converted to creatinine in the blood stream in a
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nonenzymatic-nonsaturable process. The resulting creatinine 
is easily excreted by the kidney. Also, since creatine is a 
naturally occurring component of a meat containing diet it is 
unlikely to become a banned substance. In light of these 
findings, creatine is likely to find use in many sport and 
recreational activities.
Three important, yet unanswered questions with regard 
to creatine supplementation are: What is the dose-response 
relationship? What is the washout period (How long after the 
cessation of supplementation does it take for muscle creatine 
levels to return to normal baseline levels)? What are the long­
term effects of creatine supplementation? Creatine 
supplementation studies generally employ a dose of 20g a day 
during the loading phase, apparently because this dose was 
shown by Harris et al. (1992) to increase skeletal muscle 
creatine concentration. However, this dose may be more than 
is necessary. Due to the relatively high cost of creatine 
supplementation, especially during the loading phase, it would 
be beneficial to investigate further the dose-response 
relationship of oral creatine supplementation. Also, Greenhaff 
(1994) has mentioned that skeletal muscle creatine 
concentration does not return to baseline levels for weeks
after the cessation of supplementation. Therefore the washout 
period for creatine supplementation may be from weeks to 
months. With regards to research, this may rule out 
implementing cross over designs and reversal of treatment 
designs. Finally, the long term effects of supplementing with 
creatine while training are unknown. It is interesting to note 
that creatine depletion upregulates glucose transporter and 
oxidative enzyme expression in skeletal muscle (Shields et al. 
(1975). It would be interesting to determine if long term 
creatine supplementation affects any of these parameters. 
Also, since creatine reduces the metabolic stress of exercise 
(reduced lactate, reduced VOz and reduced fatigue) it would 
b6 interesting to determine if creatine alters the conditioning 
response due to exercise. Finally, if creatine allows for more 
intense or longer training periods, due to delaying fatigue, we 
might expect training volume or long term performance to be 
affected by supplementation.
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APPENDIX A: CONSENT FORM
The Effects of Creatine Supplementation on Total 
Work Output and Metabolism During High Intensity 
Intermittent Exercise.
I_________________________________________________ , Hereby
agree to participate as  a subject in the research project 
entitled: The Effects of Creatine Supplementation on Total 
Work Output and Metabolism Purina High Intensity 
Intermittent Exercise.
I understand that I shall perform a series of high intensity 
cycle ergometer tests to exhaustion. I understand that since 
the tests are of a  high intensity nature I will experience 
fatigue and the associated symptoms (shortness of breath, 
tiredness, muscle ache). I also understand that during the test 
data collection will include: finger prick blood samples - 
finger prick blood samples will be taken with sterile lancets 
in a sanitary manner. Oxygen consumption - Oxygen 
consumption will be determined by the use of a  Quinton gas 
analyzer. Urinary creatinine - Urinary creatinine will be 
measured and will be performed on the 5 urine samples that I 
will provide.
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I understand that the risks of this study are minimal and no 
greater than that I would experience during intense physical 
exertion (for example, fatique, localized muscle ache, 
shortness of breath, soreness). I am aware that I may choose 
to discontinue my participation in the study at any time 
without any penalty or consequences.
I understand that I will be given creatine monohydrate (20g 
per day for 5 days) or a  calcium placebo (6g per day for 5 
days). Both are nutritional supplements that are available 
over the counter and do not exceed the manufacturers 
suggested maximum dosage.
I understand that the results of this study may be published, 
but upon publication or presentation of the collected data, in 
any form, my name wilt not be used. Also, if I wish, at the 
conclusion of the study I will be informed as  to the results.
I have completely read this form. I understand the purpose of 
the study and the proceedures and risks involved. I understand
that if I have any questions I may contact the researchers at 
388-2036 or 766-6328.
Signed ___________________  Date _______________________
SS# ___________________  Date _______________________
Michael C. Prevost, Principal Investigator.
Arnold Nelson, Ph.D., Co-Investigator
APPENDIX B: PHYSICAL ACTIVITY READINESS 
QUESTIONNAIRE
PHYSICAL ACTIVITY READINESS QUESTIONNAIRE
For most people, physical activity should not pose any 
problem or hazard. PAR-Q has been designed to identify the 
small number of adults for whom physical activity might be 
inappropriate or those who should have medical advice 
concerning the type of activity most suitable.
1. Has your doctor ever said you have heart trouble?
2. Do you frequently suffer from pains in yuour chest?
3. Do you often feel faint or have spells of severe dizziness?
4. Has a  doctor ever said yhour blood pressure was too high?
5. Has a  doctor ever told yo that you have a bone or joint 
problem shch as arthritis that has been aggravated by 
exercise, or might be made worse with exercise?
6. Is there a good physical reason not mentioned here why 
yuou should not follow an activity program even if yo wanted 
to ?
7. Are you over the age of 65 and not accustomed to vigorous 
exerc ise?
Can you answer yes to any of the above
q u es tio n s?____________
If so which one?_________
Signature _____________________________
D a te_____________________ .
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APPENDIX C: ANOVA TABLES 
Table C .l. A Lactate C reatine
DF Sum of Squares Mean Square F-Value P-VaTue
Time 2 1009.371 504.686 231.734 <.0001
Subject(Group) 24 52.269 2.178
Phase 1 .359 .359 2.824 .1058
Phase * Time 2 .205 .102 .807 .4581
Phase * Subject 24 3.047 .127
Table C.2. B L actate  C reatine
DF Sum of Squares Mean Square F-Value P-Value
Time 3 1752.674 584.225 340.766 <.0001
Subjeot(Group) 32 54.862 1.714
Phase 1 10.580 10.580 57.426 <.0001
Phase * Time 3 6.614 2.205 11.967 <.0001
Phase * Subject 32 5.896 .184
Table C.3. B Lactate Placebo
DF Sum of Squares Mean Square F-Value P-Value
Time 3 1926.326 642.109 230.614 <.0001
Subject(Group) 32 89.099 2.784
Phase 1 .045 .045 .271 .6060
Phase * Time 3 .509 .170 1.024 .3949
Phase * Subject 32 5.306 .166
Table C.4. C L actate C reatine
DF Sum of Squares Mean Square F-Value P-Value
Time 3 1426.420 475.473 330.564 <.0001
Subject(Group) 32 46.028 1.438
Phase 1 7.094 7.094 57.020 <.0001
Phase * Time 3 3.455 1.152 9.257 .0001
Phase * Subject 32 3.981 .124
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Table C.S. C Lactate Placebo
DF Sum of Squares Mean Square F-Value P-Value
Time 3 1618.292 539.431 194.857 <.0001
Subjeot(Group) 32 88.587 2.768
Phase 1 .073 .073 .416 .5236
Phase * Time 3 .458 .153 .865 .4695
Phase * Subject(Group) 32 5.653 .177
Table C.6. D Lactate C reatine
DF Sum of Squares Mean Square F-Value P-Value
Time 3 735.875 245.292 177.013 <.0001
Subjeei(Group) 32 44.343 1.386
Phase 1 65.551 65.551 177.016 <.0001
Phase * Time 3 36.264 12.088 32.642 <.0001
Phase * Subject(Group) 32 11.850 .370
Table C.7. D Lactate Placebo
DF Sum of Squares Mean Square F-Value P-Value
Time 3 1169.630 389.877 186.015 <.0001
Subject(Group) 32 67.070 2.096
Phase 1 094 .094 .334 .5675
Phase *Time 3 .405 .135 .480 .6985
Phase * Subjeot(Group) 32 9.001 .281
Table C.8. A V 02 Creatine
DF Sum of Squares Mean Square F-Value P-Value
TIME 2 3208.676 1604.338 105.136 <.0001
Subject(Group) 24 366.232 15.260
Phase 1 .007 .007 .003 .9544
Phase * TIME 2 .923 .462 .231 .7952
Phase * Subject(Group) 24 47.890 1.995
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Table C.9. A V02 Placebo
DF Sum of Squares Mean Square F-Value P-Value
TIME 2 3706.475 1853.237 111.867 <.0001
Subjeot(Group) 24 397.595 16.566
Phase 1 4.553 4.553 2.547 .1236
Phase * TIME 2 1.078 .539 .301 .7425
Phase * Subjeot(Group) 24 42.902 1.788
Table C.10. B V 02 creatine
DF Sum of Squares Mean Square F-Value P-Value
TIME 2 6430.809 3215.405 174.725 <.0001
Subject(Group) 51 938.535 18.403
Category for V02 1 31.558 31.558 4.699 .0349
Category for V02 * TIME 2 9.140 4.570 .680 .5109
Category for V02 * Subject.. 51 342.511 6.716
Table C .l l .  B V 02 Placebo
DF Sum of Squares Mean Square F-Value P-Value
TIME 4 8946.018 2236.505 43.062 <.0001
Subjeot(Oroup) 40 2077.498 51.937
Phase I 46.512 46.512 49.382 <.0001
Phase * TIME 4 6.867 1.717 1.823 .1434
Phase * Subjeot(Group) 40 37.676 .942
’a b le d  C.12. C V 02 Creatine
DF Sum of Squares Mean Square F-Value P-Value
TIME 4 8840.940 2210.235 113.336 <.0001
Subject(Group) 40 780.063 19.502
Phase 1 5.575 5.575 3.043 .0888
Phase * TIME 4 7.518 1.880 1.026 .4057
Phase * Subjeot(Oroup) 40 73.277 1.832
Table C.13. C V02 Placebo
DF Sum of Squares Mean Square F-Value P-Value
TIME 2 3543.328 1771.664 75.492 <■0001
Subject(Group) 24 563.234 23.468
Phase 1 22.401 22.401 4.383 .0471
Phase * TIME 2 7.317 3.659 .716 .4989
Phase * Subjeot(Group) 24 122.670 5.111
Table C.14. D V 02 Creatine
DF Sum of Squares Mean Square F-Value P-Value
TIME 11 22097.393 2008.854 20.794 <.0001
Subject(Group) 96 9274.090 96.605
Phase 1 114.990 114.990 53.744 <.0001
Phase * TIME 11 19.239 1.749 .817 .6227
Phase * Subjeot(Group) 96 205.401 2.140
Table C.15. D V 02 Placebo
DF Sum of Squares Mean Square F-Value P-Value
TIME 11 14420.758 1310.978 69.644 <.0001
Subject(Group) 96 1807.111 18.824
Phase 1 9.209 9.209 1.450 .2315
Phase * TIME 11 24.543 2.231 .351 .9710
Phase * Subject(Group) 96 609.638 6.350
Table C.16. C reatine Time to Exhaustion
DF Sum of Squares Mean Square F-Value P-Value
TEST 3 388083.819 129361.273 54.906 <.0001
Subjeot(Group) 32 75393.556 2356.049
Phase 1 114321.681 114321.681 203.578 <.0001
Phase * TEST 3 61580.819 20526.940 36.553 <.0001
Phase * Subject(Group) 32 17970.000 561.563
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Table C.17. Placebo Time to Exhaustion
DF Sum of Squares Mean Square F-Value P-Value
TEST 3 160108.556 53369.519 35.570 <.0001
Subjeot(Group) 32 48012.889 1500.403
Phase 1 272.222 272.222 2.353 .1348
Phase * TEST 3 215.222 71.741 .620 .6071
Phase * Subjeot(Group) 32 3701.556 115.674
Table C.18. C reatine Time to Exhaustion Gain
DF Sum of Squares Mean Square F-Value P-Value
TEST 3 123161.639 41053.880 36.553 <.0001
Residual 32 35940.000 1123.125
APPENDIX D: RAW DATA
Table D.1. Time To Exhaustion Data
NUMBER GROUP PHASE TEST GBOER TIME
1 C 1 A F 6 5
1 c 1 B F 116
1 c 1 C F 120
1 c 1 D F 140
1 c 2 A F 103
1 c 2 B F 220
1 c 2 C F 240
1 c 2 D F 280
2 p 1 A M 35
2 p 1 B M 90
2 p 1 C M 100
2 p 1 D M 150
2 p 2 A M 41
2 p 2 B M 90
2 p 2 C M 80
2 p 2 D M 160
3 p 1 A F 60
3 p 1 B F 120
3 p 1 C F 207
3 p 1 D F 170
3 p 2 A F 52
3 p 2 B F 100
3 p 2 C F 160
3 p 2 D F 160
4 c 1 A M 42
4 c 1 B M 60
4 c 1 C M 140
4 c 1 D M 150
4 c 2 A M 50
4 c 2 B M 150
4 c 2 C M 200
4 c 2 D M 300
5 c 1 A M 52

















































































10 C 1 A M 62
10 C 1 B M 89
10 C 1 C M 120
10 C 1 D M 142
10 C 2 A M 59
10 C 2 B M 109
10 C 2 C M 168
10 C 2 D M 290
11 P 1 A M 45
11 P 1 B M 110
11 P 1 C M 180
11 P 1 D M 250
11 P 2 A M 46
11 P 2 B M 90
11 P 2 C M 192
11 P 2 D M 240
12 P 1 A 58
12 P 1 B 157
12 P 1 C 200
1 2 P 1 D 167
1 2 P 2 A 31
12 P 2 B 160
12 P 2 C 160
12 P 2 D 180
13 C 1 A M 43
13 c 1 B M 100
13 c 1 C M 126
13 c 1 D M 165
1 3 c 2 A M 60
13 c 2 B M 145
13 c 2 C M 258
13 c 2 D M 330
14 3 1 A • 41
14 3 1 B • 70
14 3 1 C 120
14 3 1 D - 136
14 3 2 A B 52
14 3 2 B 85
(table con’d)
14 P 2 C F 100
14 P 2 D F 131
15 P 1 A F 66
15 P 1 B F 123
15 P 1 C F 141
15 P 1 D F 160
15 P 2 A F 60
15 P 2 B F 130
15 P 2 C F 150
1 5 P 2 D F 150
16 P 1 A M 35
16 P 1 B M 90
16 P 1 C M 130
1 6 P 1 D M 200
1 6 P 2 A M 38
16 P 2 B M 90
1 6 P 2 C M 120
16 P 2 D M 210
17 C 1 A 30
17 C 1 B 90
1 7 c 1 C 100
1 7 c 1 D 170
17 c 2 A 57
17 c 2 B 150
17 c 2 C F 180
17 c 2 D F 340
1 8 p 1 A M 45
18 p 1 B M 115
18 p 1 C M 120
18 p 1 D M 150
18 3 2 A M 38
18 3 2 B M 120
18 3 2 C M 140
1 8 3 2 D M 150
Table D.2. V02 Data Bout A
NUMBER GROUP TIME VOa 1 VO* 2 R 1 R2
1 C 0 4.2 4.7 0.81 1
(table con’d)
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1 C 30 22.4 21.1 0.76 0.92
1 C 45 27 26 0.92 1
1 C 60 29.6 33.5 1.03 1.23
2 P 0 5 6.1 1.05 1
2 P 15 15.4 18.32 1.14 1.05
2 P 30 25.9 22.5 1.12 1.1
2 P 45 34.2 1.23
2 P 60 43.8 1.3
3 P 0 7.2 7.7 0.74 0.8
3 P 15 21.2 22 0.84 0.89
3 P 30 29.1 32.1 0.9 1.01
3 P 45 36.7 38.1 1.04 1.23
3 P 60 38.2 1.24
4 C 0 7.7 6.4 0.87
4 c 15 12 13.5 0.99
4 c 30 19 23.2 0.98
4 c 45 26.1 27.4 1.12
5 c 0 4.5 4.2 0.8 0.91
5 c 1 5 1 5 16.1 0.9 1
5 c 30 25.7 26 1.09 1.13
5 c 45 29.5 30.1 1.25 1.2
6 p 0 7 5 0.82 0.8
6 p 15 25 23 0.97 1
6 p 30 33 32.5 1.09 1.1
6 p 4 5 43 45.1 1.2 1.21
7 c 0 6.7 9.5 0.77 0.87
7 c 15 17.2 16.6 0.83 0.79
7 c 30 21.6 23.7 0.91 0.8
7 c 45 33.4 33.4 1.09 0.96
7 c 60 38.4 38 1.22 1.3
8 c 0 4.6 4.2 0.86 0.95
8 c 15 20.1 15.2 1.07 0.9
8 c 30 28 21.5 1.2 1.2
8 c 45 29.9 1.2
9 c 0 8.2 7.5 0.87 1
9 c 15 18.6 14.6 0.9 0.9
9 c 30 26.2 18.4 1.09 0.96
9 c 45 25.7 23.5 1.3 1.1
(table con’d)
9 C 60 26.2 1.35
10 C 0 11.1 8.8 0.85 0.9
10 C 15 21.7 13.4 0.99 0.92
10 C 30 29.6 21.3 1.02 0.9
10 C 45 35.3 27.3 1.16 1.06
10 C 60 35.8 28.1 1.3 1.23
11 P 0 8.8 7 0.8 0.82
11 P 15 27.6 25.4 0.9 0.94
11 P 30 30.8 29.7 1.2 1.18
11 P 45 44.9 46.2 1.31 1.25
12 P 0 7.5 7.7 0.75 0.85
12 P 15 19.2 15.5 0.87 0.86
12 P 30 24.1 23.8 0.97 1.3
12 P 45 29 1.13
13 c 0 7 7.7 0.93 0.95
13 c 15 10.1 19 0.87 0.98
13 c 30 24.1 31 0.94 1.01
13 c 45 37.9 38.4 1.03 1.18
13 c 60 43.5 1.41
14 p 0 6.7 9.8 0.93 0.9
14 p 15 17.8 18.1 1 0.87
14 p 30 26.5 24.9 1.04 0.95
14 p 45 30.4 1.16
15 p 0 9.1 5.3 0.97 1
15 p 15 17.4 6.4 1.02 1.03
15 p 30 25.3 16.3 1.02 1.07
15 p 45 30.8 20.5 1.16 0.88
15 p 60 33.8 28.2 1.37 0.98
16 p 0 7.1 6.4 0.95 0.98
16 p 15 18.2 17.3 1.05 1.1
16 p 30 23.4 24 1.15 1.2
17 c 0 7.5 6.1 0.7 0.92
17 c 15 20 19.3 0.7 0.99
17 c 30 31.8 29.5 0.95 1.1
17 c 45 39 1.16
18 p 0 5.6 6.7 0.8 0.8
18 p 15 18.4 16.9 0.86 0.88
18 p 30 29.4 26.5 1.02 0.95
18 p 45 32.9 1.05
Table D.3. VO 2 Data Bout B
NUMBER GROUP TIME V02 1 V02 2 R 1 R2
1 C 0 6.3 4.7 0.86 1
1 C 30 20.4 16 1.04 0.98
1 C 120 29.6 21.1 1.18 0.92
1 C 210 32.5 26 1.11 1
1 C 286 29.6 33.5 1.2 1.23
1 C 390 30.1 1
1 C 480 30.1 0.99
1 C 570 30.1 0.98
2 P 0 7.9 6.7 1.03 1.01
2 P 30 33.1 34 1.07 1.04
2 P 120 42.5 42.9 1.06 1.07
2 P 210 42.2 45 1 1.08
3 P 0 8 8 0.71 0.78
3 P 30 27.6 28 0.93 0.91
3 P 120 30.7 31.2 1.1 1.17
3 P 210 36.6 37.5 1.02 1.05
3 P 300 37.8 38.2 0.99 1.1
4 c 0 6.5 6.6 0.74 0.75
4 c 30 25 18.5 1.08 0.88
4 c 120 25.3 23.8 1.09 1.01
4 c 210 28.4 1.07
4 c 300 29.7 1.05
4 c 390 29.8 1.08
5 c 0 5.6 9.8 1.18 1.04
5 c 30 40.2 36.5 1.19 1.03
5 c 120 45.5 42.3 1.22 1.07
5 c 195 54.2 48.3 1.24 1.15
5 c 300 52.1 1.21
6 p 0 6.5 5.2 0.88 0.98
6 p 30 25.9 26.2 1.01 1.03
6 p 120 33.3 34 1.05 1.05
6 p 210 35.3 37 0.99 1.06
7 c 0 5.2 7.2 0.88 0.89
7 c 30 30.6 27.9 1.06 0.86
(table con’d)
7 C 120 36.5 34.9 1.2 1.08
7 C 210 41.2 40.8 1.17 1.11
7 C 295 42.3 42.6 1.22 1.2
7 C 390 45.9 1.18
7 C 480 35.7 1.21
8 C 0 6.9 6.7 0.94 0.7
8 C 30 25.8 25 1.02 0.97
8 C 120 33 32.1 1.15 1.04
8 C 210 35.6 34 1.08 1.02
8 C 300 39.3 1.04
8 C 390 34.6 1.08
9 C 0 9.1 7 0.7 0.75
9 C 30 21.4 15.3 1 0.92
9 C 120 26.3 25.5 1.17 1.1
9 C 210 27.6 26 1.19 1.12
9 C 300 28 1.2
9 C 390 31 1.2
10 C 0 4.6 6.3 0.9 0.89
10 C 30 22.6 19.6 1.07 1.03
10 C 120 31.4 30 1.1 1.03
10 C 210 37.4 36.9 1.09 1.07
10 C 300 30.1 1.25
11 P 0 9.3 6.4 0.97 1
1 1 P 30 30 28 1.13 1.12
1 1 P 120 38.2 37.9 1.15 1.14
11 Ip 210 38.5 41 1.25 1.2
11 p 290 41 1.23
12 p 0 7.1 6.5 0.78 0.83
12 p 30 28 22.7 1.05 1.06
12 p 120 29 29.5 1.16 1.04
12 p 210 34 33.9 1.03 0.92
12 p 300 36.3 36.3 0.98 0.95
12 3 390 38 37.6 1.1 1
12 P 457 30 31 1.1 1.03
13 c 0 7.8 4.7 0.91 1.18
13 c 30 28.6 27.3 0.99 0.93
13 c 120 38.9 37.1 1.22 1.1
13 c 210 44.4 42.9 1.18 1.07
(table con’d)
13 C 280 34 45.6 1.01
13 C 390 46.2 1.1
14 P 0 5.1 6 0.93 0.9
14 P 30 22.1 22.4 1.02 0.91
14 P 120 28.9 29.5 1.2 1.02
14 P 190 27.5 30.4 1.23 1.16
15 P 0 5.1 5.4 0.93 0.86
15 P 30 22.1 25.5 1.02 1.06
15 P 120 28.9 30.9 1.2 1.01
15 P 210 26.3 34.1 1.18 1
15 P 300 31 35.5 1.2 0.96
15 P 363 28 38.7 1.23 1.06
16 P 0 7.5 5.3 1.04 0.9
16 P 30 22.9 25 0.88 1.1
16 P 120 30.7 32 0.96 1.2
16 P 210 34.9 38.4 0.91 1.18
17 C 0 6.4 7.2 0.88 0.85
17 c 30 31 30 1.14 1.08
17 c 120 38.2 36.2 1.14 1.17
17 c 210 39.4 38 1.2 1.2
1 7 c 300 43 1.23
1 7 c 390 42.8 1.28
18 p 0 5.6 6.5 0.8 0.9
18 p 30 18.4 17.5 0.86 0.84
1 8 p 120 29.4 27.8 1.02 1.04
18 p 210 32.9 27.5 1.05 1.08
18 p 295 3 6 35 1.2 1.12
Table D.4. V02 Data Bout C
NUMBER GROUP TIME V02 1 V02 2 R2 R 1
1 C 0 5.9 6.5 0.88 0.9
1 c 20 17.9 14.7 0.91 0.98
1 c 80 23.6 21.3 0.89 1.15
1 c 140 24.6 23.1 0.92 1.18
1 c 200 27.8 25.6 0.98 1.18
1 c 260 27.5 27.5 1.05 1.15
1 c 320 29 28 1.1 1.2
(table con’d)
1 C 380 27.8 1.15
1 C 440 28.1 1.2
1 C 500 29.2 1.18
1 C 560 28.7 1.24
1 C 620 28.3 1.17
1 C 680 29 1.2
2 P 0 6 5.5 1 1.1
2 P 20 25.7 26 1.07 1.06
2 P 80 34.2 33.2 1.1 0.98
2 P 140 36.9 37 1.09 1.11
2 P 200 37.4 39.2 1.1 0.99
2 P 260 41.2 1.14
3 P 0 5.5 5.1 0.95 0.79
3 P 20 22.7 24.1 0.98 0.98
3 P 80 30.4 29.5 1.19 1.08
3 P 140 31.9 31.2 1.16 1.12
3 P 200 33.2 31.2 1.15 1.04
3 P 260 33.5 34.2 12 1.1
3 P 320 34.6 34 1.18 1.15
3 P 380 38.1 38 1.23 1.2
3 P 440 39.1 41.2 1.3 1.14
3 P 500 39.3 1.23
3 P 560 40 1.2
3 P 620 35.6 1.31
4 C 0 5.7 7.4 0.9 0.94
4 c 20 19.4 19 0.96 0.96
4 c 80 24.3 23 0.95 1.1
4 c 140 26.9 25.2 1.05 1.09
4 c 200 30.8 28.8 1.02 1.03
4 c 260 32.1 31.7 1.03 1.03
4 c 320 34.7 33 1.08 1.12
4 c 380 36 35 1.1 1.18
4 c 440 34 1.18
5 c 0 4.7 5.2 0.93 0.91
5 c 20 33.5 32 1.1 1.12
5 c 80 37.8 35 1.04 1.16
5 c 140 40.8 39 1.08 1.12









































260 46 44.1 1.1 1.1
320 39.6 45.9 1.1 0.98
380 48.1 46.3 1.15 1.2
440 51.7 48 1.12 1.2
500 54.3 0.98
8.6 7.8 0.91 0.78
20 24.4 26.7 0.98 0.9
80 28.6 32.9 1.13 1. 12
140 33.3 36.1 1.13 1.14
200 34.6 38.5 1.08 1.1
260 34.6 39.6 1.12 1.1
311 37.5 39.9 1.11 1.14
380 41.1 1.08
6.5 5.4 0.89 0.95
20 23.7 22.7 0.74
80 33 32.6 1.04
140 37.1 35.1 1.13 1.17
200 39.2 37.8 1.08 1.09
260 41.2 40.5 1.04 1.21
320 43.1 41.7 1.02 1.15









7.1 6.5 0.84 0.99
20 17.9 16.5 0.82 0.93
80 27.7 27 0.9 1.24
140 31.4 30.4 1.18 1.28
200 33 32.8 1.14 1.3





9 C 0 7.3 6.5 0.9 0.86
9 C 20 18.8 16.4 0.94 0.84
9 C 80 23.5 25.4 1.17 1.21
9 C 140 24.1 24.2 1.11 1.22
9 C 200 25.1 25 1.08 1.16
9 C 260 25.3 26.1 1.08 1.1
9 C 320 28 27.5 1.04 1.1
9 C 380 29.1 28.7 1.06 1.2
9 C 440 28.4 1.04
9 C 500 29.4 1.04
1 0 C 0 7 6.2 0.92 0.86
10 C 20 15.9 13.6 0.95 0.86
10 C 80 26.5 24.3 1 1.07
10 c 140 31 29.1 1.2 1.17
10 c 200 34 30.7 1.1 1.14
10 c 260 35.3 32.1 1.14 1.12
10 c 320 30.7 33 1.17 1.3
10 c 380 34.3 1.15
10 c 440 31.3 1.17
11 p 0 5.7 6.4 0.9 0.87
11 p 20 23.9 24.3 1.12 1.13
1 1 p 80 33.8 34 1.14 1.16
1 1 p 140 34.6 34.8 1.2 1.15
1 1 p 200 34 36.3 1.07 1.08
11 p 260 40.1 40 1.06 1.07
11 p 320 40.2 39.9 1.05 1.05
1 1 p 380 42.7 43.1 1.04 1.02
11 p 440 43.3 43.2 1.02 1.01
1 1 p 500 42.1 43.7 1.03 0.96
12 p 0 6.7 5.2 0.83 0.82
12 p 20 19.2 21.6 0.86 0.93
12 p 80 26.5 28.1 1.04 1.16
12 p 140 27.9 29.3 1 1.16
1 2 p 200 26.8 29.7 0.93 1.07
12 p 260 29.5 32.7 0.94 1.02
1 2 p 320 31.1 32.4 0.91 1.04
12 p 380 30.6 33.1 0.95 1.03
1 2 p 440 33.2 33.6 0.93 1
(table con’d)
12 P 500 32.9 0.99
12 P 560 33.3 0.98
13 C 0 7.6 7.7 0.82 1.03
13 C 20 24.7 18 0.84 1.05
13 c 80 34.8 32.4 1.06 1.17
13 c 140 37.1 35.3 1.08 1.25
13 c 200 40.2 38.3 1.07 1.18
13 c 260 43 39.6 1.05 1.12
13 c 320 42.8 43.8 0.98 1.08
13 c 380 44.8 1.02
13 c 440 46.7 0.98
13 c 500 46.8 0.97
13 c 560 48.1 0.98
13 c 620 49.2 0.97
13 c 680 49 0.96
14 p 0 6.2 6.2 0.8 0.83
14 p 20 19.6 12.2 0.85 0.91
14 p 80 26.8 25.5 0.96 1.28
14 p 140 30.1 33.1 1.17 1.29
14 p 200 31.6 35.1 1.15 1.26
14 p 260 32.6 36.6 1.14 1.19
14 p 320 33 1.13
15 p 0 5.4 5.4 0.86 0.94
15 p 20 21.1 22 0.96 1
15 p 80 25.3 24.5 1.1 1.13
15 p 140 26.9 27 1.2 1.15
15 p 200 27.1 26.8 1.12 1.04
15 .... p. 260 27.8 28 1.04 1
15 p 320 28.5 28.9 1 0.97
15 p 380 29 30 1.1 1.16
16 p 0 5.5 6.7 0.9 1
16 p 20 21 22 0.99 1.02
16 p 80 27.8 27.9 1.02 1.12
16 p 140 29.2 30.2 1.1 1.2
16 p 200 32.2 32.5 1.05 1.01
16 p 260 33.9 34 1.04 0.98
16 p 320 37 36.3 1.12 1.08
17 c 0 7.6 6.7 0.82 0.78
(table con’d)
1 7 C 20 1 1 12.1 1.05 1.04
17 C 80 29.5 26.7 1 0.95
17 C 140 34.5 32.4 1.09 1.3
17 C 200 39.4 38.1 1.1 1.24
1 7 C 260 39 39 1.13 1.15
1 7 C 320 40.1 0.98
17 C 380 41 1.2
17 C 440 41.1 1.18
17 C 500 40.2 1.13
18 P 0 6.8 6.5 0.86 0.78
18 P 20 16.2 15.9 1 0.76
18 P 80 26.6 27.4 1.07 1.03
18 P 140 31.2 29.9 1.1 1.15
18 P 200 34.6 35.6 1.2 1.23
18 P 260 36 37 1.12 1.14
18 P 320 37.2 37.9 1.08 1.09
Table D.5. VO 2 Data Bout D
NUMBER GROUP TIME V02 1 V02 2 R 1 R2
1 C 0 6.1 6.5 0.81 0.86
1 c 1 5 13.2 14.7 0.86 0.98
1 c 45 20.2 19.3 0.9 0.97
1 c 75 24.1 22.1 0.99 0.96
1 c 105 26 25.5 1.05 0.98
1 c 135 26.5 26 1.12 0.93
1 c 165 27.1 27 1.07 0.94
1 c 195 28.1 27.8 1.08 0.97
1 c 225 29.8 28.5 1.12 0.92
1 c 255 28.7 29.2 1.12 0.94
1 c 285 30.4 29 1.13 0.98
1 c 315 30.6 30 1.09 0.97
1 c 345 31.7 31 1.05 0.86
1 c 375 33.4 32.8 1.07 0.93
1 c 405 34 33.7 1.05 0.99
1 c 435 34.5 0.92
1 c 465 35.7 0.98
1 c 495 35.3 I0.97
(table con'd)
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1 C 525 35.1 0.94
1 C 555 35.4 0.92
1 C 585 34.6 0.98
2 P 0 6.5 12.2 1.17 0.73
2 P 15 11 26.5 0.89 0.91
2 P 45 25.6 29.2 1 0.91
2 P 75 31.4 31.9 1.08 1.01
2 P 105 34.3 30.5 1.12 0.98
2 P 135 35.6 33.4 1.08 0.94
2 P 165 37.1 32 1.04 0.98
2 P 195 36.4 34.5 1.08 1
2 P 225 38.9 31.2 1.06 0.95
2 P 255 38.4 30.7 0.96 0.97
2 P 285 39.8 29.4 0.93 0.99
2 P 315 38.9 33.1 0.99 0.94
2 P 345 43.5 36.9 0.94 0.92
2 P 375 40.8 39.1 0.96 0.96
2 P 405 40.7 37.4 0.99 0.92
2 P 435 43.8 41.7 0.99 1.01
3 P 0 14.1 16.9 0.67 0.84
3 P 15 27 23.1 0.82 0.8
3 P 45 29.7 27.2 0.96 0.79
3 P 75 30.7 29.6 1.01 0.82
3 P 105 32.7 31 1.04 1.04
3 P 135 33.4 32.4 1.05 1.04
3 P 165 34.2 32 1.03 1.05
3 P 195 35 34.2 1.04 1.04
3 P 225 35.4 29.4 1 0.98
3 P 255 37.3 34.7 1 1.05
3 P 285 36.5 34.7 1.02 1.01
3 P 315 38.6 37.8 1.02 0.95
3 P 345 38.6 39.9 1 1.06
3 P 375 38.5 38.7 1.01 0.95
3 P 405 39.1 38.9 1 1
3 P 435 38.8 39.7 1 1.02
3 P 465 37.4 37.8 1 1
3 P 495 38 1
4 C 0 8.5 7.5 0.92 0.9
(table con’d)
4 C 15 14.5 13.5 0.98 0.96
4 C 45 18.5 19.2 1.06 0.99
4 C 75 23.6 24.3 1.09 1
4 C 105 28.6 27.9 1.08 1
4 C 135 29.4 31 1.06 0.98
4 C 165 32.4 33.1 1.109 1.02
4 C 195 32 34 1.06 1
4 C 225 33.8 33.9 1.06 1
4 C 255 33.6 34 1.09 0.99
4 C 285 35 34.7 1.06 1.05
4 C 315 34.8 35 1.08 1
4 C 345 34.4 34.9 1.06 0.99
4 C 375 35 35 1.1 1.04
4 C 405 34.5 35 1.04 1
4 C 435 37 37 1.04 0.98
4 C 465 37 1
4 C 495 36.9 1.01
4 C 525 35 1
4 C 555 37.2 1
4 C 585 36.8 1.07
4 C 680 37.2 1.02
5 C 0 5.6 5.1 0.97 0.91
5 C 15 25 20.4 1.11 0.93
5 C 45 31.3 36.9 1.21 0.99
5 C 75 39.7 37.9 1.23 1.2
5 c 105 45 44 1.25 1.12
5 c 135 46.4 46.1 1.27 1.08
5 c 165 46.3 42 1.26 1.16
5 c 195 51.6 49.7 1.17 1.15
5 c 225 53 52.2 1.22 1.18
5 c 255 53.6 51.3 1.19 1.07
5 c 285 56.3 56 1.17 1.03
5 c 315 53.1 53 1.19 0.97
5 c 345 56.3 55.5 1.15 1.19
5 c 375 55.6 55 1.14 0.91
5 c 405 60.9 60.7 1.1 1.08
5 c 435 57 56.9 1.13 1.04
5 c 465 57.7 50.3 1.09 1.02
(table con’d)
99
5 C 495 61.4 58.3 1.08 1
5 C 525 64.2 60.7 1.06 0.98
5 c 555 62.7 62 1.02 1
5 c 585 67.5 64 1.02 0.93
6 p 0 6.8 10.4 0.86 1.07
6 p 15 13.7 17.2 0.78 0.76
6 p 45 26.1 23.3 0.85 0.81
6 p 75 30.6 34.8 0.97 0.81
6 p 105 35.3 37.8 1.01 0.9
6 p 135 34.9 36.8 1.08 1
6 p 165 37.7 38 1.08 1.04
6 p 195 35.9 37 1.12 1.04
6 p 225 35.1 39.1 1.08 1.03
6 p 255 35.9 39.3 1.03 1.01
6 p 285 37.5 38.2 1 1.02
6 p 315 38.4 39 1 1
6 p 345 37.3 38.2 1.04 1.03
6 p 375 39.1 38.23 0.98 1.05
6 p 405 39.2 39 0.98 1.02
6 p 435 37.4 40 0.97 1
6 p 465 34.1 38.9 0.95 0.97
6 p 495 34.7 39.2 0.96 0.94
6 p 525 35.9 38.9 0.95 0.92
6 p 555 38 0.96
7 c 0 8.5 6.8 0.89 0.88
7 c 15 19.7 21.1 0.9 0.78
7 c 45 31.6 26.1 1.02 0.84
7 c 75 36.3 30.6 1.09 0.92
7 c 105 38 33.5 1.21 0.97
7 c 135 40.1 33.8 1.29 0.99
7 c 165 39.1 35.5 1.29 1.03
7 c 195 38.8 34.7 1.31 1.04
7 c 225 40.3 37.4 1.27 1.03
7 c 255 41.9 41.9 1.23 1.05
7 c 285 42.2 42 1.19 1.06
7 c 315 45.3 43 1.16 1.06
7 c 345 44.8 43.8 1.12 1.05
7 c 375 44.9 42.5 1.11 1.04
(table con’d)
100
7 C 405 46.3 43.1 1.06 1.04
7 C 435 46.2 43.1 1.08 1.02
7 C 465 46.5 42.1 1.02 0.97
7 C 495 47.5 41.7 1.03 0.98
7 C 525 45.5 43.5 1.03 1
7 C 555 45 40.6 1.01 0.97
7 C 585 48.2 45.8 1 0.99
8 C 0 5.8 5.8 0.86 0.78
8 C 15 16.9 15.8 0.86 0.82
8 C 45 27.2 28.2 0.89 0.84
8 C 75 33.6 29.3 1.04 0.93
8 C 105 34.9 32.3 1.08 0.99
8 C 135 37.6 34.9 1.15 1.03
8 C 165 38.9 35.3 1.17 1.03
8 C 195 39.7 37.9 1.21 1.06
8 C 225 40.9 37.7 1.21 1.05
8 C 255 41.1 38 1.17 1.04
8 C 285 43.8 40.5 1.13 1.04
8 C 315 42.5 41.8 1.17 1.04
8 C 345 43 41.6 1.12 1.04
8 C 375 43.8 41.9 1.1 1.04
8 C 405 44 41.4 1.12 1.03
8 C 435 43.9 43.3 1.1 1.04
8 C 465 42.7 1.02
8 C 495 43 1.01
8 C 525 42.7 1
8 C 555 44.5 1.01
8 c 585 42.8 0.97
9 c 0 5.3 5.1 0.98 1.01
9 c 15 14 14.1 0.83 0.92
9 c 45 18.9 18.6 0.87 0.83
9 c 75 25 22 1.02 0.86
9 c 105 21.8 24 1.14 0.98
9 c 135 28.2 24.7 1.21 1
9 c 165 28.1 24.2 1.2 1.05
9 c 195 28 26.6 1.23 1.04
9 c 225 28.8 27.3 1.21 1.06
(table con’d)
101
9 C 255 29.7 24.9 1.23 1.06
9 c 285 30.2 28.3 1.2 1.06
9 c 315 31.2 26.9 1.2 1.03
9 c 345 30 28.3 1.17 1.02
9 c 375 30.2 27.7 1.15 0.99
9 c 405 31.8 27.4 1.11 0.99
9 c 435 30.5 28.7 1.13 1
9 c 465 31 27.7 1.13 1.02
9 c 495 28.7 1.02
9 c 525 27.4 1.01
9 c 555 27.4 0.98
9 c 585 28 0.96
10 c 0 5.4 5.8 0.91 0.8
10 c 15 18.3 11.5 0.87 1.03
10 c 45 25.7 21.6 0.95 0.88
1 0 c 75 29.7 26.6 1.03 0.95
10 c 105 30.7 30.6 1.14 0.97
10 c 135 33.5 32.8 1.11 1.05
10 c 165 36.4 33.7 1.16 1.02
10 c 195 38.2 37.7 1.14 1.07
10 c 225 40.2 37.6 1.14 1.05
10 c 255 41.1 39.1 1.09 1.04
10 c 285 39.8 37.3 1.07 1.01
10 c 315 43.7 39.7 1.03 1.04
10 c 345 44.9 40.7 1.04 1.03
10 c 375 45.6 41.3 1.03 1.03
10 c 405 46 42 1.03 1.01
10 c 435 36.7 1.02
10 c 465 43.8 1.01
10 c 495 44.2 1.02
10 c 525 41.7 0.99
10 c 555 44.6 1
10 c 585 43.3 1
11 p 0 5.7 6.3 0.85 0.9
11 p 15 18.3 19.4 0.95 0.98
11 p 45 25.6 24.9 0.98 0.99
11 p 75 26.7 27.2 1.09 0.95
11 p 105 28.2 29.3 1.09 1.1
11 p 135 29 30.1 1.1 1.12
(table con’d)
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11 P 165 29.5 30.9 1.12 1.15
11 P 195 32 32 1.14 1.2
11 P 225 35 34.5 1.15 1.18
11 P 255 35.6 36 1.09 1.16
11 P 285 37 36.9 1.1 1.13
11 P 315 37.4 38.2 1.09 1.04
11 P 345 36.9 37 1.08 1.03
11 P 375 38.1 39.2 1.07 1.04
11 P 405 38.8 39.3 1.05 1.01
11 P 435 39 40 1.06 1
11 P 465 39 41 1.04 1
11 P 495 38.9 41.8 1.02 1
11 P 525 39.4 42 1.01 0.92
11 P 555 40 42.3 1.05 0.99
11 P 585 38.9 42.9 1 0.96
12 P 0 6.5 4.1 0.82 0.95
1 2 P 15 8.7 9.9 0.93 0.86
12 P 45 18.5 17.1 0.96 0.88
12 P 75 23.7 23.5 1.05 0.99
1 2 P 105 27 27.8 1.11 0.96
12 P 135 28.2 29.3 1.13 0.97
12 P 165 29.1 30.6 1.12 0.98
1 2 P 195 30 32 1.08 1
12 P 225 30.8 31.8 1.08 0.99
12 P 255 31.5 31.4 1.08 1.02
12 P 285 32.4 31.1 1.03 1.02
12 P 315 32.9 33.5 1.01 1.02
12 P 345 35 1.02
12 P 375 34.1 1.01
12 P 405 29.7 1.03
13 C 0 6.9 7.5 0.9 0.96
13 C 15 17.9 18.3 0.92 0.9
13 c 45 31.5 30.6 1.06 0.88
13 c 75 38 35.7 1.11 1
13 c 105 43 39.6 1.27 1
13 c 135 42.8 43.1 1.27 1.04
1 3 c 165 43.3 43.1 1.25 1.03
13 c 195 44.8 44.5 1.23 1.01
(table con’d)
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13 C 225 45.3 46.4 1.2 1.01
13 C 255 45.3 46.2 1.13 0.97
13 C 285 49.4 46.8 1.09 0.98
13 C 315 46.9 48.7 1.06 0.99
13 C 345 47.4 46.4 1.06 0.95
13 C 375 48.3 46.8 1.06 0.97
1 3 C 405 45 0.96
13 C 435 46.9 0.96
13 C 465 46.6 0.95
13 C 495 46.7 0.92
13 C 525 49.9 0.9
13 C 555 46.6 0.92
1 3 C 585 49.5 0.92
1 4 P 0 6 4.8 0.83 0.79
14 P 15 11.7 12.2 0.91 0.85
14 P 45 17.7 25.5 0.87 0.96
14 P 75 25 30 0.99 1.05
14 P 105 28.1 33.1 1.09 1.17
14 P 135 28.6 34.3 1.19 1.15
14 P 165 28.8 35.1 1.23 1.15
14 P 195 28.9 34.6 1.21 1.18
14 P 225 26.7 36.6 1.24 1.14
1 4 P 255 30.9 37.3 1.2 1.12
14 P 285 31.1 38 1.17 1.12
14 P 315 33.7 38.2 1.15 1.13
15 P 0 4.7 5.2 0.98 0.86
15 P 15 12.3 13.4 0.74 0.98
15 P 45 18.3 17.6 0.84 1.1
15 P 75 25.2 24.5 1.05 1.12
15 P 105 28.4 29 1.1 1.11
15 P 135 29.3 30.3 1.12 1.09
15 P 165 30.9 30.9 1.14 1.06
15 P 195 31.3 32 1.14 1.03
15 P 225 31.7 32 1.14 1.02
15 P 255 30 32.4 1.1 1.03
15 P 285 30.2 33 1.07 1.08
15 P 315 31.1 32.5 1.04 1
15 P 345 28.4 33.1 1.01 0.98
(table con’d)
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15 P 375 29 34 1.01 0.9
15 P 405 29.9 34.2 1 1
15 P 435 30.1 31 0.99 1.09
15 P 465 31 0.99
16 P 0 6.7 7.7 1 0.9
16 P 15 18.9 17.8 1.06 0.99
16 P 45 22.3 20.5 1.05 1.04
16 P 75 25.6 22.5 1.03 1.05
16 P 105 27.8 25.6 1.02 1.09
16 P 135 28 27.2 1.09 1.1
16 P 165 28 27.9 1.1 1.12
16 P 195 29.8 28 1.12 1.14
1 6 P 225 32.4 30 1.15 1.11
16 P 255 33 30.9 1.03 1.04
16 P 285 34.5 32.5 1.01 1.05
16 P 315 35 34 1 1.04
1 6 P 345 35.9 35 0.99 1
16 P 375 36 36 0.98 0.99
16 P 405 35 36 1 0.99
16 P 435 36.7 37.2 1.02 0.94
16 P 465 37 37.3 1 0.93
16 P 495 36.6 37 1 0.92
16 P 525 37 38 0.89 0.9
16 P 555 36.3 38.4 0.98 0.89
16 P 585 38 37.8 0.92 0.99
17 C 0 8.6 7.6 1.1 0.9
17 C 15 19.9 19.3 0.8 0.87
1 7 c 45 36.3 34 0.89 0.92
17 c 75 40.6 38 1.01 0.9
1 7 c 105 41.7 40.3 1.06 0.92
17 c 135 43.7 40.2 1.06 0.91
17 c 165 42.7 41 1.04 0.95
17 c 195 44.4 43.1 1.04 0.93
17 c 225 45.2 42.7 1.03 0.9
17 c 255 44 43 1.05 0.92
17 c 285 46.7 43.4 1 0.92
17 c 315 50.7 45 0.99 0.92
17 c 345 50.6 46 1.03 0.9
(table con’d)
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17 C 375 49 45.4 1.03 0.91
17 C 405 46.2 44 1.04 0.95
1 7 C 435 46.1 45.7 0.99 0.96
17 C 465 46.2 46 0.99 0.93
17 C 495 46.9 46 0.99 0.92
1 7 C 525 47.2 0.95
17 C 555 46.3 0.92
17 C 585 44 0.94
18 P 0 5.5 6.7 0.89 0.83
18 P 15 15.1 15.3 0.76 0.99
1 8 P 45 26.6 25.6 0.84 0.98
18 P 75 27 26.7 0.92 1
18 P 105 27.6 27 1.01 1
18 P 135 28 28.4 1.09 1
18 P 165 29.2 29.3 1.08 1.08
1 8 P 195 31.3 31.4 1.1 1.04
18 P 225 34.6 33.9 1.12 1.05
18 P 255 36.3 36.1 1.13 1.03
18 P 285 36.9 36.9 1.12 1.02
18 P 315 37.1 37.4 1.08 1.09
1 8 P 345 36.1 38.5 1.06 1.04
18 P 375 37 37.4 1.09 1.05
1 8 P 405 37  |38 1.05 1.05
Table D.6. Lactate Data Bout A
NUMBER GROUP DRAW# LACTATE 1 LACTATE 2
1 C 1 2 1.4
1 C 2 7.5 5.7
1 C 3 9.6 7.6
1 C 4 12.2 8.7
2 P 1 1.5 2
2 P 2 6.7 7.8
2 P 3 9.2 10.2
2 P 4 11.9 13
3 P 1 1.1 1.3
3 P 2 9.1 7.9
3 P 3 10.5 9.9
(table con’d)
3 P 4 13.1 12.5
4 C 1 3.1 2.3
4 C 2 8.3 6.7
4 C 3 9.2 7.2
4 C 4 13.3 8.1
5 C 1 2 1.9
5 C 2 5.6 5.2
5 C 3 8.2 6.4
5 C 4 9.6 7.1
6 P 1 1.5 2.1
6 P 2 5.9 5.5
6 P 3 8 7.8
6 P 4 11.9 10.2
7 C 1 2.1 1.2
7 C 2 6.7 4.2
7 C 3 8.3 6.5
7 C 4 12.6 8.5
8 C 1 1.8 2.3
8 C 2 8 6
8 C 3 10.1 5.9
8 C 4 14.1 9
9 C 1 1.5 1.2
9 c 2 5.6 5.6
9 c 3 10.1 7.2
9 c 4 13.2 8.8
10 c 1 2.1 2
10 c 2 6.2 7
1 0 c 3 9.1 7.7
10 c 4 12.1 8.4
11 p 1 2.3 1.8
11 p 2 5.9 6
1 1 p 3 8.4 8.5
1 1 p 4 11.9 12
12 p 1 1.9 3
1 2 3 2 7.2 6.9
12 3 3 10 9.8
12 p 4 14.1 14.2
13 c 1 2.1 1.5
(table con’d)
13 C 2 _ 8 8
13 C 3 11.4 9.2
1 3 C 4 13.2 10
14 P 1 1.1 2
14 P 2 6.7 7
14 P 3 9.9 10.1
14 P 4 12.2 11.9
15 P 1 3 2.1
15 P 2 8.9 9
1 5 P 3 12.1 11.9
15 P 4 14.7 13.9
16 P 1 1.8 1.6
16 P 2 5.7 7.8
16 P 3 8.7 8.9
16 P 4 12.2 13
17 C 1 2 2.2
1 7 c 2 7.9 6.7
17 c 3 10.4 7.4
17 c 4 13.2 8.9
18 p 1 1.6 1.4
18 p 2 7.3 7.8
18 p 3 11.1 10.8
18 P |4 14 14.1
Table D.7. Lactate Data Bout B
NUMBER GROUP DRAW# LACTATE 1 LACTATE 2
1 C 2 9.9 8
1 C 1 1.2 1.4
1 C 4 16 14.7
1 C 3 11 9.9
2 P 3 10.4 9.8
2 P 4 14.5 13.9
2 P 1 1.8 1.8
2 P 2 8.7 9
3 P 3 10.9 11
3 P 4 17.1 17.2
3 P 1 3.2 2.2
(table con’d)
3 P 2 9.9 9.5
4 C 3 12.2 11.5
4 C 4 15.2 14.5
4 C 1 2.1 2
4 C 2 9.3 8.1
5 C 2 8.5 7.3
5 C 1 1.3 2.2
5 C 4 13.2 13.5
5 C 3 12.1 10
6 P 3 1 3 13
6 P 4 14.2 14
6 P 1 2.2 2.3
6 P 2 8.4 9
7 c 3 13.2 13
7 c 4 15.6 13.2
7 c 1 1.1 1.9
7 c 2 10 9.1
8 c 3 14.1 13.5
8 c 4 16.7 14
8 c 1 1.5 2.2
8 c 2 12.5 10.8
9 c 3 12.9 11.8
9 c 4 15 14
9 c 1 2.4 1.8
9 c 2 10.1 8.9
10 c 2 9.3 8.5
10 c 1 1.1 1.4
10 c 4 15.1 14.3
1 0 c 3 13.9 12.9
11 p 3 13.9 13.7
11 p 4 16 17.2
1 1 p 1 1.9 1.3
1 1 p 2 7.9 8.1
12 p 2 9.3 8.9
12 p 1 2 2.1
12 3 4 17.2 17
12 3 3 12.8 13
13 c 3 14 13.4
(table con’d)
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13 C 4 15.1 14.2
13 C 1 1.1 1.4
13 C 2 11.1 9.9
14 P 3 12 11.6
14 P 4 14.2 1 5
14 P 1 1.3 1.2
14 P 2 9.3 9.9
15 P 3 15.1 16
15 P 4 18.1 17.6
15 P 1 1.8 2.2
15 P 2 9.8 9.9
16 P 2 7.9 8
16 P 1 2.3 1.9
16 P 4 15.1 14.7
16 P 3 13.1 13.6
17 C 3 14.6 14
1 7 c 4 15 1 4
17 c 1 IZ2 2
17 c 2 10.3 9
18 p 2 9.5 9.6
18 p 1 1.7 1.3
18 p s 14 16
18 p 3 14.2 14
Table D.8. Lactate Data Bout C
NUMBER GROUP DRAW# LACTATE 1 LACTATE 2
1 C 1 1.5 1.2
1 C 2 7.8 7.2
1 C 3 10.5 10.1
1 C 4 15.1 13.9
2 P 1 2.3 2.1
2 P 2 7 7.4
2 P 3 9.2 9.8
2 P 4 13.4 13.5
3 P 1 2.2 2
3 P 2 9.7 9.5
3 P 3 10.5 10.3
(table con’d)
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3 P 4 16 17.2
4 C 1 1.2 1.4
4 C 2 8.8 7.9
4 C 3 11.2 10.3
4 C 4 14.2 13.1
5 C 1 1.8 1.4
5 C 2 7.2 7
5 C 3 10.5 9.8
5 C 4 11.5 11.2
6 P 1 2 1.9
6 P 2 7.4 7.3
6 P 3 10 9.8
6 P 4 13.4 13.1
7 C 1 1.7 2.1
7 C 2 8.9 8
7 C 3 12.1 11.2
7 C 4 14.5 12.8
8 C 1 2.5 3
8 C 2 10 9.5
8 C 3 13.1 12.1
8 C 4 15.9 14.2
9 C 1 3 1.5
9 C 2 8.1 7.9
9 C 3 11.8 10.1
9 C 4 14.6 13
10 C 1 1.4 2.3
10 C 2 9 8.5
10 C 3 12.9 12
10 C 4 13.8 13.1
11 P 1 2.2 2.1
11 P 2 7.2 7.3
11 P 3 11.5 11.5
11 P 4 13.9 14
12 P 1 2 1.3
12 3 2 8 7.8
12 3 3 11.4 11.1
12 3 4 15.7 15.3
13 c 1 1 1.7
(table con’d)
111
13 C 2 9.6 9.1
13 C 3 12.2 11.7
13 c 4 14.6 13.6
14 p 1 1.1 1.1
14 p 2 8.5 9
14 p 3 10.9 1 1
14 p 4 13.2 14.2
15 p 1 1.6 3.1
15 p 2 9 8.4
15 p 3 13.5 12.9
15 p 4 15.6 15.9
16 p 1 3 2.1
16 p 2 7 6.8
16 p 3 12.2 12
1 6 p 4 14.1 15
17 c 1 2.1 2.1
17 c 2 9.9 9.1
17 c 3 12.1 1 1
1 7 c 4 14 13.4
18 p 1 1.8 1.2
1 8 p 2 10 9.5
18 p 3 15.1 13.9
18 p 4 16.8 15.7
Table D.9. Lactate Data Bout D
NUMBER GROUP DRAW# LACTATE 1 LACTATE 2
1 C 1 2 1.4
1 C 2 7.5 5.7
1 C 3 9.6 7.6
1 C 4 12.2 8.7
2 P 1 1.5 2
2 P 2 6.7 7.8
2 P 3 9.2 10.2
2 P 4 11.9 13
3 P 1 1.1 1.3
3 P 2 9.1 7.9
3 P 3 10.5 9.9
(table con'd)
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3 P 4 13.1 12.5
4 C 1 3.1 2.3
4 C 2 8.3 6.7
4 C 3 9.2 7.2
4 C 4 13.3 8.1
5 C 1 2 1.9
5 C 2 5.6 5.2
5 C 3 8.2 6.4
5 C 4 9.6 7.1
6 P 1 1.5 2.1
6 P 2 5.9 5.5
6 P 3 8 7.8
6 P 4 11.9 10.2
7 C 1 2.1 1.2
7 C 2 6.7 4.2
7 C 3 8.3 6.5
7 C 4 12.6 8.5
8 C 1 1.8 2.3
8 C 2 8 6
8 C 3 10.1 5.9
8 C 4 14.1 9
9 c 1 1.5 1.2
9 c 2 5.6 5.6
9 c 3 10.1 7.2
9 c 4 13.2 8.8
10 c 1 2.1 2
10 c 2 6.2 7
10 c 3 9.1 7.7
10 c 4 12.1 8.4
11 p 1 2.3 1.8
1 1 p 2 5.9 6
11 p 3 8.4 8.5
1 1 p 4 11.9 12
1 2 p 1 1.9 3
12 3 2 7.2 6.9
12 3 3 10 9.8
12 3 4 14.1 14.2
13 c 1 2.1 1.5
(table con’d)
113
13 C 2 8 8
13 C 3 11.4 9.2
13 C 4 13.2 1 0
14 P 1 1.1 2
14 P 2 6.7 7
14 P 3 9.9 10.1
14 P 4 12.2 11.9
15 P 1 3 2.1
15 P 2 8.9 9
15 P 3 12.1 11.9
15 P 4 14.7 13.9
16 P 1 1.8 1.6
16 P 2 5.7 7.8
16 P 3 8.7 8.9
16 P 4 12.2 13
17 C 1 2 2.2
17 c 2 7.9 6.7
17 c 3 10.4 7.4
1 7 c 4 13.2 8.9
18 p 1 1.6 1.4
18 p 2 7.3 7.8
18 p 3 11.1 10.8
18 p 4 14 14.1


































1 1 2 278.9
1 1 3 112.3
12 1 212.3
12 2 87.6
1 2 3 156.7
1 3 1 333
13 2 1000.6
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